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ABSTRACT 
 
Background: OA is a complex disorder with multiple risk factors including 
obesity. Obesity has been implicated for early OA due to mechanical and metabolic 
effect of the fat through low-grade inflammation. Also, synovitis and inflammation 
have gained a lot of popularity in the research field as a cause of OA.  
Aims: 1: To determine the effect of BMI on the synovial vascularity and 
inflammation among different age groups with advanced OA. 2- To determine the 
effect of fat cell size on the vascularity and inflammation. 3- To assess the difference 
in synovitis among young obese, young lean and old lean people with advanced OA.  
Methodology: A total of 17 patients (matched for gender, the advanced stage of 
OA requiring total knee arthroplasty, KL score, comorbidities, ASA grade, 
medications and functional outcome score) have been recruited into three almost 
equal groups based on age (young <60, old >70) and BMI (lean <30, obese >30). 
Group 1 (young obese (n=6)) with age and BMI mean (SD) 53.3 (2.33) and 38.53 
(1.16) respectively. Group 2 (young lean (n=5)) with age and BMI 55.60(4.5) and 
27.01(1.59) respectively. Group 3 (old lean (n=6)) with age and BMI 75.33 (3.2) and 
25.64 (2.5) respectively. The synovial tissues obtained during surgery were examined 
using H&E staining and IHC staining of vWF, CD34, CD68, CD3, CD20 and vimentin. 
Quantitative assessment of each marker was done using image J software in the 
synovial tissue sections, fat tissue sections and combined total sections. Also fat cell 
size was measured and divided into small and big fat cells. The IHC markers were 
also analyzed based on the fat cell size. Other manual counts were done for the 
vessels in the synovial and fat sections. Vessels diameter and distance to the synovial 
surface were measured too.   
Results:  The overall vascularity did not show any significant difference across 
the groups (p=0.468). There was significant difference of vimentin across the groups 
(p=0.006). The other inflammatory markers showed a trend of increasing with 
increase BMI. However, macrophages, T cells, B cells and fibroblasts were 
significantly higher in the presence of big fat cells (p= 0.035, 0.016, 0.046, 0.014 
respectively). The vascular density was significantly higher in the fatty sections with 
big fat cells (p= 0.028).  Inflammatory markers showed positive correlation with BMI 
and negative correlation with age. The vascular density and the distance to the 
synovial surface showed a trend of increasing in the young obese group. There was 
trend of increasing vascular wall thickness in the young obese group which was also 
observed in the correlation. 
Conclusion: The synovium of the obese patients showed more inflammatory 
response but the vascularity was not significantly different. Increased fat cell size 
significantly attracted inflammatory cells. Vascular hyperplasia (increased wall 
thickness) is an indication of atherosclerosis in the synovial vessels. 
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1. INTRODUCTION 
 
Osteoarthritis (OA) is a very common musculoskeletal disorder typically affecting 
older people and leading to disabilities. It is the most common form of arthritis. OA is 
not a single condition or a disease but rather a common complex disorder with 
multiple risk factors. The risk factors are broadly divided into genetic factors, 
constitutional factors and local factors (National Clinical Guideline, 2014). These can 
also be considered as modifiable and non-modifiable factors. The modifiable factors 
include obesity, lifestyle, repetitive micro-trauma and joint surgery (Michael et al., 
2010, Heidari, 2011). Although OA is linked to old age, young people can also get it. 
It is usually secondary to trauma and multiple injuries to the joints. Primary OA can 
also affect young people and this is seen more in obese individuals (Blagojevic et al., 
2010).  
 
Obesity has become a pandemic with many effects on health and the economy 
(Meldrum et al., 2017). Obesity has also been implicated in the early development of 
OA. It has been investigated extensively and multiple theories have been proposed 
on the aetiology of OA in this group, which are mainly divided into either mechanical 
or systemic causes. The evidence in favour of mechanical causes suggests that obese 
individuals are more than twice as likely as non-obese people to develop OA 
(Blagojevic et al., 2010). One pound of weight loss unloads 4 pounds of joint stress in 
people with knee OA, leading to reduced pain (Messier et al., 2005). Similarly, a loss 
of as little as 11 pounds in women reduced the incidence of OA by half (Felson and 
Zhang, 1998). Moreover, obese patients have greater sagittal-plane knee moments 
and greater knee joint load than normal weight adults (Browning and Kram, 2007).  
 
Furthermore, a longitudinal study conducted in Michigan from 1962 until 1985 
showed that obesity was significantly associated with the 23-year incidence of OA in 
the hands among subjects who were disease free at baseline. Greater baseline 
weight was also associated with greater subsequent severity of OA of the hands 
(Carman et al., 1994). In the US National Health and Nutrition Examination Survey 
(NHANES), wave III (1988–1994), data from over 7,000 adults suggested that each 
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component of metabolic syndrome (the medical term for a combination of diabetes, 
high blood pressure and obesity) was more prevalent in people with OA (Puenpatom 
and Victor, 2009). Moreover, the histological characteristics of the synovium (the 
membrane lining the synovial joint) taken from patients with OA and those with mild 
RA were similar (Haraoui et al., 1991). All these factors suggest a systemic cause of 
OA, which is chronic inflammation associated with obesity, referred to as metabolic 
OA. In the knee joint, the infrapatellar fat pad ( a collection of fat behind the patellar 
tendon and below the patella inside the knee joint) is an established source of 
adipokines, which are capable of modulating inflammatory and destructive 
responses in knee OA through low-grade inflammation (Goldring and Otero, 2011, 
Clockaerts et al., 2010). At the molecular level, the fat tissues in obese patients 
release adipokines (cell signalling proteins secreted by adipose tissue), which are 
recognised by the innate immune system and can initiate a pro-inflammatory 
response. Excess fat leads to activation of macrophages to change to M1 phenotype, 
which is pro-inflammatory in nature (Kanneganti and Dixit, 2012).  
 
Despite numerous studies looking into obesity and OA, the knee joint synovium 
of young obese people has not been examined thoroughly before. It would be 
interesting to know if there is a difference between the synovium of young obese 
and lean people. This topic attracts several questions related to obesity and OA. For 
example, why do young obese people get early OA whilst old lean people present 
with OA very late? Are there any differences in their synovium that make one group 
do better than the other? How is inflammation related to the local fat burden?  
 
To address these questions, multiple Immunohistochemical factors have been 
examined in this work. Immunohistochemistry was used to examine the synovium of 
young obese, young lean and old lean people to look at angiogenesis, inflammatory 
cells and synovitis. Angiogenesis was examined as overall vascularity using CD34 and 
activated vessels using von Willebrand Factor. One marker was used to quantify each 
inflammatory cell: CD3 for T cells, CD20 for B cells, CD68 for macrophages and 
vimentin for fibroblasts.  
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The complexity of conducting this research was obvious from the start as we 
were dealing with a diverse group of patients with different backgrounds and 
possibly different causes of OA. A lot of attention was placed on matching all the 
groups to be able to reach conclusions regarding the differences.  
 
These markers were studied in detail to identify differences and correlations 
between groups in relation to age, body mass index (BMI) and fat cell diameter. 
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2. LITERATURE REVIEW 
 
2.1 Osteoarthritis (OA) 
OA is a very common musculoskeletal condition. In the UK, about 8.75 million 
people (33%) aged 45 and above have sought treatment for OA and 60% of them 
were females, according to The State of Musculoskeletal Health 2017 (Arthritis 
Research UK) (UK, 2017). In the US, it is estimated that nearly 27 million people have 
clinical OA (an increase from the estimate of 21 million in 1995) (Lawrence et al., 
2008). This shows the magnitude of the problem of OA, which is continuing to grow, 
especially with the increased life expectancy. There is no doubt that this will lead to 
a considerable cost and burden to the affected individuals and the state. Data from 
Schofield and colleagues showed that the income of people have retired owing to 
arthritis is five times less than that of those who are still working. Furthermore, the 
loss of workforce productivity, lost income tax revenue and increased government 
support to these individuals cost the state considerable amount of money (Schofield 
et al., 2013). In developing countries and poor nations, where patients do not have 
access to treatments such as joint replacements, the impact of arthritis is significant, 
placing a tremendous burden on communities (Fejer and Ruhe, 2012). 
 
2.1.2 Pathophysiology 
 
OA is characterised by progressive loss of articular cartilage and the formation of 
osteophytes, which lead to chronic pain and functional restrictions in the affected 
joints. It involves matrix fibrillation, fissure appearance, gross ulceration and full 
thickness loss from the joint surface (Martel-Pelletier, 2004). The exact mechanism 
of cartilage breakdown in OA is still not very clear. It is a complex interaction of a 
multitude of factors, including genetic, environmental, metabolic and biochemical 
and mechanical factors (Sandell and Aigner, 2001, Kapoor et al., 2011, Loeser et al., 
2012). The pathophysiological process of OA can be divided into three overlapping 
stages, as summarised by Martinek: the first stage starts at the molecular level with 
degradation of the matrix network. The size of aggrecan (a matrix molecule) 
decreases and the water content increases, which affect the mechanical properties 
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of the articular cartilage, making it less stiff. As a result, in the second stage, 
chondrocytes try to compensate by increased proliferation and metabolic activity. 
This condition can remain for several years. Finally, in stage three, the chondrocytes 
are not able to keep up their repair activity and a complete loss of cartilage tissue 
occurs as a consequence (Martinek, 2003).  
 
A multitude of risk factors lead to OA development, which can be divided into 
controllable and uncontrollable factors. The former include trauma, repetitive micro-
trauma, overweight and obesity, joint surgery, such as meniscectomy, bone density, 
muscle weakness and lifestyle. The uncontrollable factors include age, genetics, 
gender, hormonal changes and ethnicity (Michael et al., 2010, Heidari, 2011). These 
factors work together to determine the risk for OA.  
 
OA was thought to be a wear and tear problem originating in the articular 
cartilage as a consequence of either any process that would cause an abnormal load 
on any particular joint or owing to fragility and degeneration of articular cartilage. 
This paradigm changed with the advent of molecular biology and the discovery of 
many soluble mediators, such as cytokines, that can increase the production of 
matrix metalloproteinases (MMP) by chondrocytes (Berenbaum, 2013). This has led 
to the theory of inflammation as a cause of OA.  
 
One of the obvious signs of an inflammatory process is the presence of synovitis 
and joint effusion, a feature linked to inflammatory arthropathies like rheumatoid 
arthritis. Synovitis has been observed in early- and end-stage OA and involves 
infiltration of mononuclear cells into the synovial membrane and production of pro-
inflammatory mediators, including interleukin 1β (IL-1β), tumour necrosis factor-α 
(TNF-α) and chemokines. Other inflammatory markers have been observed in the 
synovial fluid but with lower abundance when compared to in RA patients. They are 
MMP-1, MMP-3 and MMP-13, cysteine cathepsins B and S, as well as IL-6, which 
reflect the importance of inflammation as a cause of arthritis (Pozgan et al., 2010). 
Synovitis is observed in OA during flare-ups of the condition. The inflamed synovium 
produces pro-inflammatory mediators such as nitric oxide, prostaglandin, 
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neuropeptides and cytokines, which cause increased production of the proteolytic 
enzymes responsible for cartilage breakdown. This in turn amplifies synovial 
inflammation, creating a vicious circle (Sellam and Berenbaum, 2010). It was found 
that high sensitivity C-reactive protein levels reflect synovial inflammation and are 
associated with pain level (Pearle et al., 2007). The reason that the synovium 
becomes inflamed in OA is still under debate. It has been hypothesised that the 
trigger is a cartilage fragment that acts as a foreign body, leading to activation of the 
synovium to produce pro-inflammatory mediators that then activate the 
chondrocytes to produce the degrading enzymes, which will further breakdown the 
cartilage (Sellam and Berenbaum, 2010). Another hypothesis suggests that the 
problem originates in the synovium, as evidenced by the link of macrophages in OA 
where macrophage-depleted synovium did not generate MMP-induced neoepitopes 
in a mouse experiment (Mapp and Walsh, 2012). It is difficult to know for certain 
where OA starts in the joint. However, it is important to examine the joint in a 
holistic manner and look at it as an organ with multiple parts that interact with each 
other to maintain function.  
 
The innate immune system (see the inflammation section) was found to play a 
role in OA. A study has shown that TLR levels are increased in OA cartilage lesions. 
Other TLRs, including low molecular weight hyaluronic acid, fibronectin, tenascin-C 
and alarmins (S100 proteins, high-mobility group protein B1 [HMGB1]), have been 
found in OA synovial fluid. They are known to induce inflammatory responses. S100 
proteins are involved in synovial activation and cartilage destruction (Kim et al., 
2006, van Lent et al., 2012). Many other studies have shown links between the 
innate immune system and OA (Nair et al., 2012, Wang et al., 2011, Rosenthal, 
2011).  
 
Another theory of OA is the low-grade inflammation has been proposed based 
on an interesting study that looked into the gene expression profiles in peripheral 
blood leukocytes from patients with OA compared with a non-OA control group. 
There were two distinct subgroups of peripheral blood leukocytes in the OA group 
(Attur et al., 2011). In the same study overexpression of IL-1β was associated with 
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higher pain scores and increased risk of OA progression. This leads us to obesity as a 
risk factor for OA owing to the chronic low-grade inflammation. However, 
mechanical load also has been implicated in obesity.  
 
2.1.3 Obesity and OA 
 
Obesity has received significant attention as an important risk factor for OA 
development, especially after the identification of adipose tissue as an endocrine 
organ that is able to produce biologically active substances called adipokines 
(Goldring and Otero, 2011). The infrapatellar fat pad is an established source of 
adipokines and is capable of modulating inflammatory and destructive responses in 
knee OA. Low-grade inflammation has been attributed to circulating adipokines 
(Clockaerts et al., 2010). In the same study by Clockaerts and colleagues, the 
infrapatellar fat pad was found to contain macrophages, lymphocytes, granulocytes 
and nociceptive nerve fibres, which could in part be responsible for anterior pain in 
knee OA. In addition, the infrapatellar fat pad secretes cytokines, interleukins, 
growth factors and adipokines that influence cartilage by up-regulating the 
production of MMPs, stimulating the expression of pro-inflammatory cytokines and 
inhibiting the production of cartilage matrix proteins. The end result is cartilage 
degradation. Although adipose tissue could cause a low-grade inflammatory process, 
other mechanisms may also contribute to OA in obese people. Along with the loss of 
muscle mass and strength over time, obesity is associated with mechanical stress. All 
these possible pathways could propagate OA (Vincent et al., 2012).  
 
Mechanical load and movement are essential to the survival of the chondrocytes. 
Based on in vitro mechanical loading experiments, injurious static compression 
stimulates the depletion of proteoglycans and damage to the collagen network, and 
decreases the synthesis of cartilage matrix proteins. On the other hand, dynamic 
cyclic compression increases matrix synthetic activity (Torzilli et al., 2010). Impact 
injury can lead to chondrocyte death through the release of reactive oxygen species 
(ROS), which are responsible for up regulating MMP-13, ADAMTS-5, and TNF-α (Ding 
et al., 2010). One could argue that in obese people, cyclical load is taking place, 
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which would help maintain the articular structure. It is difficult to assume this as the 
mechanics of the joints can also be affected, leading to abnormal cyclical loading. It 
is also worth noting that weight loss improves OA symptoms (Messier et al., 2005). 
Weight reduction reduces pain and increases physical function (Messier et al., 2000, 
Christensen et al., 2007). It was found that compressive forces through load-bearing 
joints such as the knee are reduced by almost fourfold due to weight loss (Messier et 
al., 2005). There is no doubt that obesity is an important risk factor for OA and it 
involves complex interconnected pathways. Moreover, obesity is a component of 
metabolic syndrome. Metabolic syndrome (MetS) describes a number of related 
conditions, such as insulin resistance, visceral obesity, dyslipidaemia and 
hypertension, which on their own significantly increases a patient’s risk of 
cardiovascular disease. People with metabolic syndrome are at a higher risk of 
having OA (Puenpatom and Victor, 2009). OA that is related to obesity and metabolic 
syndrome is called metabolic OA and is considered as a subtype of OA. In fact, 
metabolic OA has been proposed to be the fifth component of metabolic syndrome 
(Zhuo et al., 2012). 
2.1.4 Smoking and OA 
 
In a recent article by Dube et al. (Dube et al., 2016), the negative effect of 
smoking on OA was summarised in five possible mechanisms: 1) Effects of smoking 
on cartilage loss as evidenced by knee MRI findings that showed a significant 
association between cartilage loss and pack-year smoked (Davies-Tuck et al., 2009). 
2) Smoking triggers genetic predisposition to OA as shown by Ding et al. (Ding et al., 
2007), where MRI showed reduction in the cartilage volume in people who smoke 
and have a family history of OA a study that shows gene-environment interaction in 
the aetiology of knee OA. 3) Smoking’s effects on inflammation are very well 
established and profound. Cigarette smoke produces thousands of ROS, which has a 
significant impact on the immune system and activation of inflammation (Lee et al., 
2012, Huang et al., 2005). 4) Smoking is also associated with metabolic syndrome 
and both insulin resistance and higher BMI. The risk of metabolic syndrome reduces 
upon smoking cessation (Chiolero et al., 2008). 
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2.2 Anatomy 
 
Figure 2. 1:  Anatomy of the knee joint showing the synovial layer, adapted from(Choy and 
Panayi, 2001) 
 
Synovial joints are unique structures. They are lubricated connections between 
bones and are the reason for our flexibility. They are fluid filled cavities separating 
layers of hyaline articular cartilage. It is suggested that they first evolved as 
vertebrates moved onto land (Askary et al., 2016). There are different hypotheses as 
to where they first evolved and the prevailing hypothesis is that lubricated synovial 
joints first evolved in tetrapods in response to newfound mechanical challenges 
imposed on the weight-bearing joints of nascent limbs (van der Kraan, 2013a, van 
der Kraan, 2013b). An old histological study suggested that jaw joints of lungfish 
have a synovial-like morphology (Bemis, 1986). The latest findings suggest that they 
evolved even earlier than what is currently accepted (Askary et al., 2016). 
 
The knee joint is a modified hinge joint that allows flexion, extension and 
rotation, yet provides complete stability and control over a wide range of loading 
conditions (Goldblatt and Richmond, 2003). The stability is derived from the shape of 
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the bone as well as the surrounding soft tissues, such as muscles and ligaments. 
Within the knee joint, there is specialised membrane (synovium) that lines the inside 
of the knee joint and provides it with the synovial fluid that is essential in the knee 
mechanics and the viability of the articular cartilage. In general, the term synovium 
refers to the soft tissue lining the spaces of diarthrodial joints, tendon sheaths and 
bursae (Smith, 2011). It includes the continuous superficial layer of cells (intima) and 
the underlying tissue (subintima). The intima consists of macrophages and 
fibroblasts while the subintima includes blood and lymphatic vessels, a cellular 
content of both resident fibroblasts and infiltrating cells in a collagenous 
extracellular matrix (Smith, 2011). The normal synovial membrane is stated to be a 
relatively acellular structure consisting of a distinct intimal lining layer of one to two 
cells thickness and a synovial sublining layer. The latter is relatively acellular, 
containing scattered blood vessels, fat cells and fibroblasts, with few lymphocytes or 
macrophages. Typically, the normal synovium contains an intimal layer of 20–40 µm 
thickness in cross-section and an areolar subintima, which can be up to 5 mm in 
thickness.  
 
The normal synovial tissue can be divided into three different categories 
microscopically. This depends on the structure and content of the subintimal layer. It 
can be fibrous, areolar and adipose. In some areas of the body, the subintima may 
consist of periosteum, perimysium or even hyaline or fibrocartilage. The areolar type 
of normal synovium is the most specialized form; most of the time it is folded and 
can unfold when stretched. There is usually a continuous layer of lining cells, often 
two or three deep, on the tissue surface (called the intima) (Smith et al., 2003, 
Smith, 2011). Immediately beneath the intimal layer are capillaries, with a deeper 
plexus of small arterioles and venules, associated with mast cells (Davies, 1950, 
Wilkinson and Edwards, 1989). Lymphatic vessels are present in all types of normal 
synovial tissue and are usually found in the deep subintima. The extracellular matrix 
of normal synovium has different consistencies in different layers. Type I collagen is 
scant in the intimal layer and more abundant in the subintimal layer. The deepest 
area of the normal synovium consists of a loose connective tissue layer, which allows 
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the membrane to move freely. Below this loose layer there will often be found 
ligament, tendon or periosteum (Smith, 2011).  
Electron microscopy of the synovium by Barland and colleagues (Barland et al., 
1962) showed that the lining cells are divided into two cell types or states of activity 
on the basis of their cytoplasmic contents. Type A synoviocytes with a phagocytic 
function and type B synoviocytes, which are responsible for secretory functions in 
the synovium. The former can be found in the macrophage lineage and the latter in 
the fibroblast lineage.  
 
In normal synovium, macrophages make up a minority of cells, while the 
numbers increase significantly in inflammatory arthritis. For example, in RA synovial 
tissue, macrophages account for up to 80% of the intimal layer. The usual pattern is 
that of a superficial layer of macrophages with an intimal phenotype, below which is 
a layer of intimal fibroblasts. In OA synovium, the inflammatory cells are also more 
especially macrophages (Farahat et al., 1993). There is good evidence to suggest that 
the macrophages in the synovium originate from circulating monocytes, which come 
from the bone marrow.  
 
Fibroblasts (Type B synoviocytes), have adapted to the production of hyaluronan 
(Wilkinson et al., 1992). Synovial fibroblasts are different from the normal 
population of fibroblasts as they express adhesion molecules that are not seen in the 
normal population. These are thought to be important in cellular trafficking as they 
trap macrophages and lymphocytes in the synovium but allow neutrophils to egress 
to the synovial fluid (Edwards et al., 1997). Other types of cells are found in the 
synovium, including T and B lymphocytes, which are thought to play a role in 
trafficking in the normal synovium. Dendritic cells are also found in the synovium 
(Smith, 2011).  
 
The extracellular matrix in the intimal layer is composed of a variety of fine 
fibrillar ultrastructures, including collagens III, IV, V and VI with a little type I 
collagen. There are other structures in the intima, including laminin, fibronectin and 
chondroitin-6-sulfate-rich proteoglycan, which are all components of the basement 
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membrane (along with collagen IV), but there is no basement membrane beneath 
the intimal layer in normal synovium (Revell et al., 1995). 
The vasculature of the synovium is unique with some fenestrated capillaries 
located just beneath or within the intima. This type of vascular anatomy allows for 
the communication between the immune system with the synovial joint. The 
vascularity increases in the deeper layer. In the subintimal layer, there are larger 
venules, arterioles and lymphatics. They form an anastomosing array (Xu et al., 
2003). Capillaries are very prominent in inflammatory arthropathies such as RA. 
Essentially, any inflammatory process will cause proliferation of endothelial cells, 
which is addressed in this research in relation to fat levels.  
 
The functions of normal synovium are: providing a deformable structure to allow 
movement of nearby relatively non-deformable tissue structures because of the 
specialised viscoelastic characteristics of materials like collagens in the synovium, 
maintenance of an intact non-adherent tissue surface, joint lubrication, control of 
synovial fluid volume and composition, and chondrocytes. The non-adherent tissue 
surface is achieved by the production of hyaluronan by the intimal B synoviocytes. 
The latter cells also produce plasminogen activator and decay accelerating factor 
(DAF), which may inhibit fibrin formation and scarring. The maintenance of the 
synovial fluid is a delicate process where there is a free exchange of crystalloids and 
proteins, and inhibition of the rapid transit of viscous hyaluronan solution, which is 
an important component of the fluid. This is achieved by intimal fibroblasts and 
macrophages. The unique structure of the vascularity also plays a role in getting the 
maintenance of this fluid through recruitment of inflammatory cells such as 
macrophages from the blood monocytes. 
 
The lubrication of the synovial joint is an important function of the synovial fluid 
to enable long-lasting, functioning frictionless joints. The size-selective semi-
permeable membrane of the synovium is an important part of the synovial fluid 
formation. The synovial fluid (SF) is a dialysate of blood plasma with contribution 
from the molecules secreted by the cells lining and within the synovial tissue. It 
contains lubricant molecules, namely hyaluronan and proteoglycan 4, also known as 
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lubricin, and superficial zone protein (Schumacher et al., 1994, Jay et al., 2000, Hui et 
al., 2012). These are high molecular weight molecules and are trapped in the 
synovial joint while low molecular weight molecules can leave the join, including 
most metabolic substrates and byproducts, cytokines and growth factors. The 
synovial membrane also acts as a barrier against high molecular weight plasma 
molecules entering the joint. In the disease process, this mechanism of strict control 
does not function properly, leading to alteration of the synovial fluid contents and 
characteristics (Hui et al., 2012).  
 
Synovial fluid is a viscous, non-Newtonian fluid (i.e. shear stress is reduced with 
increased shear rate). Thus, the SF behaves as a viscous material at low rate of 
oscillation and as elastic martial at high frequencies. This is also called shear-thinning 
behaviour and occurs in normal and OA synovial fluid. These properties are mainly 
owing to the concentration and molecular mass of hyaluronan (Schurz and Ribitsch, 
1987). On the other hand, SF in RA exhibits a Newtonian behaviour.  
 
2.2.1 Articular cartilage 
 
Although this research is mainly focused on the synovium, the anatomy of the 
articular cartilage has to be mentioned to better understand the structure. The 
articular cartilage is a unique structure that has a smooth surface. It is avascular, 
aneural, alymphatic and almost non-immunogenic. It receives its nutrition from the 
synovial fluid circulating in the joint. It is a composite material with cells embedded 
in an extracellular matrix. Chondrocytes represent the cellular component of the 
articular cartilage. The extracellular matrix (ECM) is composed of fibres and ground 
substance. Collagen, especially type II, is the main fibre, representing about 10–20% 
of the wet weight. Other fibres such as elastin are also present. The major 
constituent of the ECM is water (representing about 75% of the wet weight). Ground 
substance includes water, proteoglycans and glycosaminoglycans, glycoproteins, 
degradative enzymes like MMPs and extracellular ions.  
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The articular structure can be divided into four layers histologically. These layers 
are: the superficial layer (gliding zone), the middle layer (transitional zone), the deep 
layer (radial zone) and the calcified layer (calcified zone). The arrangement of the 
collagen fibres is different in each zone to adapt to the function of the joint during 
movement. The fibres are parallel to the articular surface in the superficial zone to 
resist shear stress. This arrangement changes gradually from parallel to oblique in 
the transitional zone to end up in a perpendicular direction to the articular surface. 
The latter helps to resist compression forces (Ramachandran, 2007).  
 
As there is no blood supply to the articular cartilage, self-renewal is limited to 
poor quality regeneration, which lacks the capacity to withstand normal 
physiological stresses (Lorenz and Richter, 2006). Although the avascular feature of 
the articular cartilage seems to be a disadvantage for cartilage repair, it is actually a 
very intelligent design. If we imagine, for the sake of argument, that the articular 
cartilage is full of blood vessels, this will put it at risk of bleeding with any 
physiological load. This, of course, is not a good idea as we know that bleeding in the 
joint will lead to early OA, which is very well documented in cases of haemophilia. To 
avoid bleeding, the vessels have to be protected with something hard, like what 
happens in the bone, but this will defeat the purpose of the smooth and soft 
articular cartilage. Thus, the articular cartilage relies on the neighbouring synovium 
to do the job of nutrition through the synovial fluid. The synovial fluid brings 
nutrients and components of cellular repair to the chondrocytes by diffusion. The 
chondrocytes are metabolically very active, but normally do not divide after 
adolescence. They can repair only small defects associated with minimal loss of 
matrix components. More extensive defects will result in permanent damage to the 
articular surface (Wollheim, 1999). 
 
2.3 Microcirculation 
2.3.1 Basic vascular anatomy 
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Microcirculation refers to the vascular bed where vessel diameters are smaller 
than 100 μm. They are designed to reach tissues at the cellular level to transport 
oxygen and nutrients and remove cellular waste (das Gracas Coelho de Souza et al., 
2016). They are very sensitive to changes in systemic blood pressure, which is 
readjusted by the vascular tone to meet the local oxygen requirements. The blood 
vessels exhibit dynamic changes to adapt to the physiological demand. Their lumen 
is covered by endothelium, which is formed by a monolayer of endothelial cells 
(ECs). The ECs are very important to the physiological changes that happen to the 
local microcirculation. Their position between the blood stream and the vascular 
smooth muscle cells (VSMCs) makes them capable of sensing physical and chemical 
stimuli from either side of the lumen (Deanfield et al., 2007, das Gracas Coelho de 
Souza et al., 2016). The microvessels are subdivided into arterioles, capillaries and 
venules. Arterioles are the start of the microcirculation system and are responsible 
for controlling the blood flow to the tissue. The arteriolar ECs are surrounded by 
VSMCs, which contract and relax in response to the vasoactive factors released by 
the nervous system (den Uil et al., 2008). The arterioles continue as capillaries, 
which are formed by one EC layer surrounded by a basement membrane. It is this 
anatomical feature that allows them to carry out the exchange of molecules 
between blood and tissue. The lumen diameter is about 5 μm. Finally, the capillaries 
end up as venules, which join the bigger veins. Thus, for the vessel to qualify for the 
function of exchange of molecules, it should not contain a smooth muscle layer (den 
Uil et al., 2008). Figure 2.1 shows the details of the anatomy. 
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Figure 2. 2:  Anatomy of microcirculation 
 
2.3.2 Microcirculation in the synovium 
 
This has been discussed briefly in the anatomy section (section 2.2). Levick 
(Levick, 1995)explained the details of the synovial microcirculation and how it is 
related to the actual function in normal and abnormal conditions. The synovium has 
a very rich microvascular bed composed of capillaries and post-capillary venules. In a 
normal human knee synovium, the vascular density average 240 mm-2. These 
capillaries are very close to the synovial surface. In normal individuals the average 
distance is 35 µm but this distance is more than double in RA. The average transport 
distance in chronic RA is more than twofold that of the normal synovium and the 
density is reduced by one third. About 50% of the capillaries in the synovium are 
fenestrated and the rest are continuous. The fenestration is usually facing the 
synovial surface. All these features are essential to facilitate the exchange of fluid 
and to provide the chondrocytes with nutrition.  
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2.3.3 Adipose tissue and microcirculation 
 
Adipose tissue is considered as an endocrine organ that secretes a lot of 
adipokines, which are capable of inducing inflammation. The excessive accumulation 
of adipose tissue noted in obesity leads to adipocyte hypertrophy, which results in a 
decrease in the vascular density and hence the blood flow, which will eventually lead 
to adipose tissue hypoxia. As a result, adipocyte necrosis will occur, which 
potentiates an inflammatory response (Ouchi et al., 2011). This inflammatory 
response will result in atherosclerosis, which will further worsen the local blood 
supply. It is interesting to know that weight loss in obese people will lead to an 
improvement in the structure of the vessels (De Ciuceis et al., 2011). Although 
atherosclerosis affects blood vessels systemically, local factors can play a role. All 
blood vessels except the cerebral vasculature have an outer fatty layer called 
adventitia. It is also called perivascular fat or perivascular adipose tissue (PVAT)(Gao, 
2007). It was believed that PVAT provides only structural support to the vessels. 
However, in cases of obesity, vascular injury, aging and infection, the PVAT causes 
adipocyte abnormality and activation of inflammatory response, which lead to VSMC 
growth and proliferation, which, in turn, can cause vascular disease including 
atherosclerosis, restenosis and hypertension (Miao and Li, 2012). VSMCs can also be 
modulated by the endothelial cells and the nerve fibres (Feletou et al., 2008).  
 
2.4 Inflammation 
 
Inflammation is a coordinated process induced by microbial infection or tissue 
injury (Nathan, 2002, Vinay Kumar, 9th Edition). It is a complex process whereby the 
body aims to repair itself relying on different mechanisms. There are two main 
systems that act harmonically to reach a state of homeostasis. The innate immune 
system is the first line of defence against any external or internal stimuli. It has a 
broad-spectrum function against internal and external injuries. It is believed to 
stimulate the adaptive immune system to target specific microbes and retains a 
memory of the pathogen to act faster when it recurs, but this adaptive system take 
longer to activate in the first instance (Alberts B, 2002). 
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2.4.1 The Innate immune system 
 
The innate immune system is an ancient system that is present in all protozoa. As 
a first line of defence against all microorganisms and external injuries, it has a 
specific mechanism by which it can act quickly and recognise pathogens. This 
happens through pattern recognition receptors (PRR), which detect the pathogen-
associated molecular patterns (PAMPs) exhibited by microorganisms (Medzhitov and 
Janeway, 2000). The PAMPs represent molecular structures that are produced only 
by the microbial pathogens, but not by the host organism. For example, the bacteria 
but not the eukaryotic hosts produce peptidoglycans and liposaccharides. This 
property of PAMPs accounts for self-/non-self-discrimination by the adaptive 
immune system of vertebrates as well. They represent conserved molecular patterns 
that are essential for the survival of the microbes. PAMPs are often shared by large 
groups of microorganisms, which allows the immune system to develop a limited 
number of germ line-encoded pattern recognition receptors to recognise the vast 
variety of microorganisms. The molecular structure of the PAMPs represents a 
signature of a pathogen class that allows the immune system to choose the best 
defence mechanisms against a given class (Medzhitov and Janeway, 2000, 
Medzhitov, 2007).  
 
PRRs are germline-encoded receptors evolved in host organisms to recognise 
PAMPs. They are heterogeneous proteins with different domains involved in pattern 
recognition (Medzhitov and Janeway, 2000). They can be involved in: 1) opsonisation 
of bacteria and viruses for phagocytosis or activation of the lectin pathway of 
complement (Fraser et al., 1998), 2) uptake of pathogens by phagocytes and 
dendritic cells (Stahl and Ezekowitz, 1998), or 3) triggering of the signalling pathways 
that result in the induction of transcription of a variety of immune response genes.  
 
The body has to distinguish between self and non-self, and starts an 
inflammatory response to suit the situation. Inflammation can be triggered by 
infection, trauma, post-ischemic injury, toxins and autoimmune injury. The innate 
immune system is activated after such injury either through the PAMPs or other 
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factors that are released following trauma, such as heat shock proteins, HMGB1, 
neuropeptides and mast cell contents, including histamine, leukotrienes, PGD2, 
tryptases chemokines and TNF. The immune system has evolved to control infections 
or any other injury in a rapid way but alongside the control of the infection or injury 
there is also damage to local tissue by the inflammatory response. Thus, the immune 
system has to distinguish between infection and a simple trauma and then has to 
decide how bad the injury is or whether there is a combination of both infection and 
trauma. The immune system has to act quickly and control the injury as soon as it 
gets activated by the factors listed above. This happens through recruitment of 
leukocytes from the blood (Muller, 2003). However, to act fast the leukocytes should 
be residing in the tissue. Mast cells and macrophages fulfil this function. Once an 
injury occurs, the mast cell releases its content with all the pro-inflammatory factors 
and starts activating other inflammatory cells. The first cell to arrive to the injury site 
is the neutrophil, which further amplifies the inflammatory response by activating 
the mast cells and also releasing other chemotactic agents to recruit more 
inflammatory cells. The neutrophils undergo respiration, where they release 
proteinases, other hydrolases and oxidants. This action leads to tissue breakdown. 
The macrophages are activated and also help in the amplification of the 
inflammatory response. The antigen-presenting cells are attracted to the site of 
injury or infection, and in turn activate lymphocytes to act in a more targeted way 
against specific pathogens, leading to less unnecessary damage to the surrounding 
tissue.  
 
Accordingly, there are four distinct phases of the inflammatory cascade: 
recognition of infection using the aforementioned mechanisms by the PRRs, 
recruitment of inflammatory cells to the site of infection, elimination of the microbe, 
and resolution of inflammation and return to homeostasis (Vinay et al., 2015). One 
of the functions of the innate immune system is to activate the adaptive immune 
system to help in controlling the inflammatory cascade. 
 
33 | P a g e  
 
2.4.2 The adaptive immune system 
 
The two main cellular components of the adaptive immune system, T and B cells, 
both play major roles in protective immunity against infectious pathogens and have 
the potential to eradicate cancerous cells (den Haan et al., 2014). It is the function of 
the innate immune system to activate this highly specific system to aid in eradicating 
any infectious focus, although it is not always necessary to activate the innate 
immune system to activate the adaptive system (Alberts B, 2002).  
 
The T and B cells are activated by professional antigen-presenting cells, such as 
dendritic cells (DCs). The classical antigen-presenting cells are DCs, macrophages, 
Langerhans cells and B cells (Wollenberg and Bieber, 2002). In recent years, DCs have 
been found to regulate the cross talk between the innate and the adaptive immune 
system (Boltjes and van Wijk, 2014). Out of all the antigen-presenting cells, the DCs 
are the most potent in promoting activation of naïve T cells (Boltjes and van Wijk, 
2014). The understanding of DCs has evolved since 1968 when studies Mosier and 
Coppleson showed that accessory adherent cells were required for in vitro immune 
responses (Mosier and Coppleson, 1968). It was thought that these cells are 
macrophages, but they were later found to be DCs (Hoefsmit et al., 1982). Gene 
expression analyses, lineage tracing and barcoding experiments further indicated 
their existence as a separate hematopoietic lineage (Schraml et al., 2013, Naik et al., 
2013). These cells identify the antigen then process it and present it to the 
lymphocytes for degradation. This process has been established very well (Neefjes et 
al., 2011, Vyas et al., 2008). It is clear that in acute inflammation the innate immune 
system is activated very quickly to contain the infection through the aforementioned 
mechanisms. However, the immune system is still working even if there is no 
external stimulus or antigen. It works to keep the body safe even from itself. The 
metabolites of cell metabolism can be harmful and there has to be a mechanism by 
which the body can take care of them. In this case, it is very important to have 
antigen-presenting cells, especially the DCs that are spread all over the body, to keep 
the body safe, even in the steady state. This leads us to the theory of low-grade 
inflammation as an important cause of OA.  
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2.4.3 Inflammation and angiogenesis 
 
Angiogenesis and inflammation are very closely related processes and have 
gained increasing attention in recent years. This link was observed a long time ago 
with the appearance of newly formed blood vessels in granulation tissue, and the 
dual functionality of angiogenic factors, i.e., they exhibit both pro-inflammatory and 
pro-angiogenic effects (Granger and Senchenkova, 2010). Although the two 
processes are completely different, they potentiate each other.  
In normal tissue, capillary growth and proliferation are rarely noticed except 
during acute injury and wound healing or cyclical events in the female reproductive 
cycle; with appropriate stimuli, the process of angiogenesis can be started. This 
process is controlled by different factors, which can promote or inhibit angiogenesis. 
Thus, there has to be a balance between the angiogenic and angiostatic factors to 
determine the existence and rate of blood vessel proliferation in a tissue. During the 
inflammatory process, the balance is in favour of angiogenesis. It is believed that the 
hypoxic state in inflammation acts as a stimulus for angiogenesis through the 
hypoxia-inducible factor signaling pathway, which elicits the transcription-
dependent production of VEGF and FGF. In addition, inflammation is also associated 
with the recruitment of circulating leukocytes and platelets, and the activation of 
resident macrophages, mast cells and fibroblasts, all of which are capable of 
producing large quantities of pro-angiogenic factors, including VEGF and cytokines 
(Naldini and Carraro, 2005, Lingen, 2001). 
 
Angiogenesis relies mainly on the vascular endothelial growth factor (VEGF) 
family and its receptors (VEGFR-1 and VEGFR-2) for its regulation. Under direct 
stimulation from VEGF-A, the endothelial cells start proliferating, a process that 
requires engagement of VEGFR-2 with VEGF-A to activate tyrosine kinase, leading to 
sprouting of new vessels from existing microvessels. A prerequisite for sprouting is 
destabilisation of existing microvessels, which includes pericyte dropout, diminished 
cell–cell adhesion and dissolution of the basement membrane. So, the endothelial 
cell starts to leave the endothelial monolayer by penetrating through the basement 
membrane and invading the nearby interstitial space. The cell retains a specific 
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phenotype to enable it to produce lamellopodia. The latter extend ahead of the cell 
to sense the environment and determine the appropriate migratory direction. This 
cell acts as a foundation and is followed by migratory/proliferative cells, which allow 
for extension of the sprouting vessel and lumen formation. VEGF plays a major role 
in the process of sprout formation. The majority of the angiogenic effects of VEGF 
are mediated through VEGFR-2 which, along with VEGFR-1 activation, are necessary 
for the hyper-permeability associated with this process. There is recent evidence 
suggesting that bone marrow-derived cells are implicated in the formation of new 
blood vessels in chronic inflammation (Chidlow et al., 2007, Dvorak, 2005, Hicklin 
and Ellis, 2005). 
Chronic inflammation and angiogenesis are two different processes that work 
hand in hand. The two processes are stimulated by hypoxia, leading to the 
accumulation of macrophages and other immune cells and an increase in growth 
factor production (Murdoch et al., 2005). There is abundant evidence to support the 
contribution of these factors, which are released in the inflammatory process, to 
vascular endothelial cells (Philip et al., 2004, Coussens and Werb, 2002, Nathan, 
2002). In other words, angiogenesis potentiates inflammation by providing oxygen 
and nutrients to help in the cellular metabolism of the inflammatory cells. It starts 
with the production of nitric oxide (NO) by the inflammatory cells. NO is a potent 
inflammatory agent, which, along with other inflammatory cytokines, stimulates 
vessel dilatation and permeability to allow immune cells to escape to the injury site 
(Charo and Taubman, 2004). The inflammatory cells require adhesion molecules for 
them to escape the vessels to the injury site in a process involving cell rolling, 
tethering and firm adhesion to the vascular wall of the endothelial cells, and finally 
extruding out of the lumen. Different types of pro-inflammatory factors control the 
adhesion molecules. Once the inflammatory cells are activated and reach the battle 
field, they release angiogenic factors, such as VEGF, Ang, bFGF, HGF, PDGF, TGF- 
beta, TGF-alpha and many others, at the inflammatory site, which induce mitogenic 
and migratory effects in the endothelium (Lee, 2005). As mentioned above, hypoxia 
is one important feature of inflammation, inducing the up-regulation of hypoxia-
inducible factors expression, which leads to transcription of several angiogenic genes 
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encoding for VEGF and other angiogenic factors (Coussens and Werb, 2002, Naldini 
and Carraro, 2005). 
 
A primary event in inflammation is activation of nuclear factor kappa-B (NF-kB), a 
transcription factor, by the pro-inflammatory mediators. It is crucial for regulating 
gene expression of a wide range of genes important in cell survival, including MMPs, 
urokinase type plasminogen activator, V-CAM, I-CAM and E-selectin 
molecules.(Charo and Taubman, 2004, Charo and Ransohoff, 2006, Karin, 2006). The 
end result is a continuous production of inflammatory and angiogenic molecules and 
the activation of MMPs, which degrade the extracellular matrix. There is growing 
interest in chronic inflammation and angiogenesis as the number of pathologies 
involving them are increasing. OA is an example of such pathologies.  
 
OA is the most common type of arthritis and is thought to be degenerative in 
nature (Creamer and Hochberg, 1997). The aetiology of OA is multifactorial; 
however, inflammation is increasingly considered as a cause of arthritis progression 
(Smith et al., 1997, Benito et al., 2005, Brooks, 2003, Myers et al., 1990). The 
synovial membrane of OA showed inflammatory infiltrates primarily of T cells and 
monocytes in over 50% of patient sample’s as shown by (Myers et al., 1990). There is 
also evidence of increased C-reactive protein in OA patient sera and correlated with 
OA progression. (Spector et al., 1997). In addition, several pro-inflammatory 
cytokines and chemokines have been detected in the synovial infiltrates in OA, 
including IFN, IL-1, IL-6, IL-8, IL12, IL-17 and TNF-alpha (Smith et al., 1997, Myers et 
al., 1990). These pro-inflammatory molecules act on specific receptors present on 
ECs, cartilage and bone cells, leading to the production of MMPs and plasminogen 
activator, which as mentioned before degrade the ECM and impair the structure and 
function of the cartilage (Vergunst et al., 2005). 
2.5 IHC markers of interest 
2.5.1 Endothelial cells 
2.5.1.1 Von Willebrand factor (vWF) 
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vWF is a glycoprotein essential for haemostasis. It can result in bleeding disorder 
if deficient of defective (von Willebrand disease). The basic vWF monomer contains 
2050 amino acids. This large multimeric glycoprotein is produced constitutively as 
ultra-large vWF (it is assembled from identical approximately 250 kDa subunits into 
disulfide-linked multimers that may be >20,000 kDa.) in the endothelium and 
specifically in the Weibel–Palade bodies within the endothelial cells. It is also 
produced by megakaryocytes (α-granules of platelets) and sub-endothelial 
connective tissue (Sadler, 1998). 
 
 To understand vWF and its relation in our study, it is essential to understand the 
inflammatory process and what happens at the molecular level with the endothelial 
cells. Endothelial cells are important in monitoring the inflammatory response as 
they respond to changes in mechanical and chemical stress. The endothelial cell 
contains unique organelles called Weibel–Palade bodies (WPBs) in which the vWF is 
synthesised and stored. In fact, 95% of the contents of the WPBs are made up of 
vWF and its precursor propolypeptide (Proregion) with small amounts of other 
adhesion and signalling molecules like P-Selectin and IL8. WPBs are rod-shaped 
organelles between 100 and 300 nm thick and can be up to 4 μm long with internal 
tubules (approximately 15 nm thick) running parallel to the long axis and are 
embedded in an electron-dense matrix. They are restricted to endothelial cells and it 
was believed that they have an important role in vascular physiology, which was 
proven after the discovery of vWF within the organelles (Weibel and Palade, 1964, 
Jaffe et al., 1973).  
 
The WPBs contain an important protein that is very critical to initiation of 
inflammation. This protein is P-Selectin, which is a membrane protein of the WPBs 
that is involved in the recruitment of leukocytes to the activated endothelial cells. 
Once stimulated, WPBs fuse with the plasma membrane and P-selectin appears on 
the cell surface within 20 min of stimulation. The P-Selectin tethers leukocytes to 
endothelial cells and subsequently rolling of leukocytes on endothelia, a step that is 
essential in cell trafficking and initiation of inflammation (Hannah et al., 2002). 
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Moreover, upon stimulation of endothelial cells, the contents of the WPBs (i.e. 
vWF) are secreted, which mediates the adhesion of platelets to sites of vascular 
damage by binding to specific platelet membrane glycoproteins and to constituents 
of exposed connective tissue. It is the size of vWF that makes it suitable for this 
function. VWF is also a carrier protein for blood clotting factor VIII, and this 
interaction is required for normal factor VIII survival in the circulation and hence 
haemostasis (Hannah et al., 2002). 
 
WPBs exocytosis is a complex process. It involves some form of fusion of the 
organelles with the plasma membrane that allows the release of the contents. There 
are two types of fusion: kiss and run fusion, in which case the fusion pores open and 
close rapidly, and a lingering kiss that allows the fusion pore to remain open for a 
longer period of time. The type of fusion that happens in the case of WPB is more of 
a lingering kiss. It is interesting to know that the fusion pores formed during the 
lingering kiss can act as filters that retain bigger molecules, like vWF, and release 
others. The lingering kiss events are proportional to the strength of the stimulus 
(Babich et al., 2008). 
 
The above evidence suggests that the vWF is very specific to endothelial cells and 
is a very specific marker to assess the activity of endothelial cells and also the 
amount of inflammation associated with it. In our research, we will look into this 
marker and carry out a quantitative assessment of the activated endothelial cells, 
and then relate it to the inflammatory process in the tissue sections. 
 
2.5.1.2 CD34 
CD34 was first identified in hematopoietic progenitor cells as a transmembrane 
phosphoglycoprotein. It was described independently by (Civin et al., 1984, Tindle et 
al., 1985) as a surface protein that functions as a cell–cell adhesion molecule. It has 
been studied extensively and has been found to be expressed in cells other than 
stem cells. Although CD34 is considered predominantly as a marker of hematopoietic 
stem cells, it is now an established marker of several non-hematopoietic cell types, 
such as vascular endothelial cells, embryonic fibroblasts, multipotent mesenchymal 
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stromal cells, interstitial dendritic cells and epithelial progenitors. It belongs to a 
family of single-pass transmembrane sialomucin proteins (Sidney et al., 2014). 
Despite extensive investigation, CD34’s actual function is still not very clear. 
However, it has been linked to inhibition or facilitation of adhesion, cell proliferation 
and regulation of differentiation (Healy et al., 1995, Nielsen and McNagny, 2009). 
 
CD34 has been investigated for sensitivity and specificity in diagnosing vascular 
tumours and was found to be a reliable marker for assessing vascularity (Miettinen 
et al., 1994, Fina et al., 1990). Although CD34 is expressed mainly in the luminal 
membrane of cellular processes, it may also be expressed on the luminal membrane 
of cells at the tip of the vascular sprouts. Those endothelial cells with CD34 markers 
are thought to be quiescent and involved in migration and adhesion (Fina et al., 
1990). This implies that CD34 gives an overall assessment of the vascularity of a 
given tissue but it does provide information about the endothelial cell activity in 
terms of neo-angiogenesis. The main objective of this research is to explore the 
angiogenesis, and CD34 and vWF markers have been chosen for this purpose. The 
CD34 marker focuses on the overall vascularity whereas vWF assesses only activated 
endothelial cells. 
2.5.2 Macrophages 
2.5.2.1 CD68 
 
Macrophages are white blood cells and are considered as one of the big eaters of 
the immune system. They are differentiated from the monocytes, which are in turn 
originated from the bone marrow progenitor cells. Macrophages live in every tissue 
of the body. In case of tissue damage or infection, monocytes are rapidly recruited to 
the tissue, where they differentiate into tissue macrophages. The role of 
macrophages in inflammation has been established and discussed earlier in the 
literature review (see inflammation section 2.4). Macrophages play an important 
role in the synovium as inflammatory cells that regulate inflammation. They are 
considered as a principal morphological characteristic of synovitis (Benito et al., 
2005). Benito and colleagues (Benito et al., 2005) studied the differences between 
early and late OA and found that synovial lining thickness and CD68 expression are 
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significantly higher in early OA. They control cytokines, which drive cartilage 
breakdown. Although other cells also produce these cytokines, such as chondrocytes 
and fibroblasts, macrophages are considered the key stimulator of these processes 
(Sun et al., 2016). The role of macrophages in OA has been discussed in the section 
of pathogenesis of OA (section 2.1). 
 
Macrophages have different phenotypes and functions and have the capacity to 
change phenotype depending on the local tissue circumstances; hence, they are 
referred to as heterogeneous cells. They are classified into M1 and M2. M1 
macrophages are pro-inflammatory whereas M2 macrophages are anti-inflammatory 
(Liu et al., 2014).  
 
CD68 was used as a classic marker of macrophages in the synovial tissue. ‘This 
gene encodes a 110-kD transmembrane glycoprotein that is highly expressed by 
human monocytes and tissue macrophages. This protein primarily localises to 
lysosomes and endosomes with a smaller fraction circulating to the cell surface. It is 
a type I integral membrane protein with a heavily glycosylated extracellular domain 
and binds to tissue- and organ-specific lectins or selectins. The protein is also a 
member of the scavenger receptor family. Scavenger receptors typically function to 
clear cellular debris, promote phagocytosis, and mediate the recruitment and 
activation of macrophages’(HGNC:1693). 
 
CD68 is not a macrophage-specific marker (Kunisch et al., 2004): it is expressed in 
other cells, such as fibroblasts. Different anti-CD68 monoclonal antibodies are 
commonly used to detect macrophages using IHC. They are KP1, EBM11 and PGM1. 
Kunisch and colleagues (Kunisch et al., 2004). studied them in terms of specificity of 
expression by the macrophages and other cells. They found an overlap between 
CD68 (MoAb KP1 and EBM11) and the fibroblast marker CD90. On the other hand, 
PGM1 MoAb was less expressed by the synovial lining fibroblasts. Therefore, CD68 
(MoAb PGM1) was selected for use in this research to obtain the true representation 
of the macrophages in the synovial tissue. 
41 | P a g e  
 
2.5.3 Fibroblasts 
2.5.3.1 Vimentin  
 
Vimentin is a protein encoded by the VIM gene in humans. It is an intermediate 
filament that is expressed in mesenchymal cells. It is part of the cytoskeleton that 
maintains the cell structure (Fuchs and Weber, 1994). It is essential for human and 
animal cells to maintain cell structure to be able to protect the integrity of the 
cellular components. This has created a challenge to the tissues and resulted in a 
mechanism to cope with mechanical stress. Human and animal tissues have the 
capacity to withstand mechanical stress as a result of the presence of the 
intermediate filaments. The cells in any tissue are not floating in the matrix. Instead, 
there are cell–cell junctions, such as demosomes, adherens junctions, gap junctions 
and tight junctions. Along with the intermediate filaments, these junctions create 
integrated cellular networks that have the stability and flexibility to withstand 
normal physiological mechanical stresses (Herrmann et al., 2007).  
 
Vimentin is highly expressed by fibroblasts with some expression in T- and B-
lymphocytes. It also has an essential role in wound healing as it coordinates 
fibroblast proliferation and keratinocyte differentiation (Cheng et al., 2016). Ivaska 
and colleagues (Ivaska et al., 2007) reviewed the novel functions of vimentin and it is 
interesting to know that it is not exclusively associated with the mechanical and 
structural properties of the cells. It participates in cell adhesion, migration and 
invasion, signalling, differentiation, cytoskeletal rearrangements, and regulation of 
cell morphology and plasticity. One of the important functions related to this 
research is tissue repair in patients with arthritic joints. Thus, vimentin is expressed 
more by the fibroblasts in the synovium in cases of tissue repair, especially in 
arthritis where the damage is continuous. It would be interesting to know how 
vimentin is related to other inflammatory cells in the synovium as it is essential in 
cell migration and adhesion. Table 2.1 summarises its functions (Ivaska et al., 2007). 
Table 2.1: Summary of vimentin functions in different physiological processes and 
tentative or identified molecular interaction targets involved in the observed 
effects (Ivaska et al., 2007) 
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Cellular function Target of regulation Effect 
Structural integrity of cells 
and tissues 
 
Endothelial cell junctions 
and/or ECM interaction 
Integrity of cell layers and 
tissues 
Adhesion and migration 
 
Integrins, cell adhesion 
molecules, cytoskeletal 
crosslinking proteins 
Formation and turnover of 
adhesive structures 
 
Signal transduction 
 
Transcription factors 
 
Modulation of activity 
through sequestration 
Protein kinases 
 
Operation and organisation 
of kinases 
14-3-3 Modulation of 14-3-3 
interactions 
Receptors and receptor-
associated proteins 
Formation of a functional 
cell surface complex 
Apoptotic and immune 
defence 
 
Cell death-regulating factors Modulation of activity 
through sequestration 
  
Viral components 
 
Regulation of subcellular 
localisation 
Extracellular domains Activation of innate immune 
system cells 
Regulation of genomic DNA Genomic DNA 
 
DNA recombination and 
repair 
 
2.5.4 B and T cell lymphocytes 
2.5.4.1 CD3 
 
CD3 is very well studied and is an integral part of the panel of markers used in 
the analysis of lymphoid malignancy. It is associated with the human T-cell receptor. 
The T-cell receptor (TCR) is present in almost 95% of T-lymphocytes as a surface 
membrane complex. It consists of an α–β heterodimer and at least four 
monomorphic, invariant T3 or CD3 molecules (y, δ, ε, ζ). It appears likely that the TCR 
α–β molecule alone determines both antigen recognition and major 
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histocompatibility complex (MHC) restriction on at least some T cells. Chemical 
cross-linking studies of CD3-positive T-lymphocytes that are unreactive with 
monoclonal antibodies against the TCR α–β molecule revealed that the TCR y and δ 
genes are also associated with the CD3 glycoprotein complex. The α, β and CD3 
receptor subunits are transmembrane proteins, and all but the ε subunit have N-
linked glycan moieties (Chetty and Gatter, 1994). 
 
CD3 is a very specific antigen that is strongly expressed in the T-cell lineage. 
However, there is weak expression in Purkinje cells in the brain, macrophages, and 
Hodgkin’s and Reed–Sternberg cells. It is expressed as a surface membrane in 
mature T cells. Immunohistochemical studies have shown that CD3 is present in the 
cytoplasm before expression on the cell surface. 95% of thymocytes express surface 
membrane and/or cytoplasmic CD3 positivity. The presence of intracellular CD3 has 
suggested that the cell is going in the direction of the T cell lineage. CD3 helps in the 
response of T cells to antigenic stimulation through signal transduction. It delivers a 
biochemical signal from the surface to the inside of the cell after the antigen has 
bounded to the receptor. CD3 also helps in antigen recognition by the T-cell 
lymphocytes along with the antigen receptors forming a complex, which are linked 
non-covalently. CD3 antigen specificity for T cell and its early appearance in T-cell 
maturation makes it an ideal pan-T-cell marker for T-cell neoplasm. Cabecadas and 
Isaacson (Cabecadas and Isaacson, 1991) identified three key T-cell antibodies: CD3, 
UCHL1 and MT1. They assessed their efficacy in histopathological diagnosis of 
lymphoid and non-lymphoid tissues. UCHL1 (CD45RO) and MT1 (CD43) are not 
lineage-specific and react with both lymphoid and non-lymphoid cells. MT1 stains T-
cell areas specifically in cases of reactive lymphoid tissue. However, MT1 is not 
lineage-specific as it cross-reacts with granulocytes, megakaryocytes, brain cells and 
cases of high- and low-grade. B-cell UCHL1 is also non-lineage specific because it 
cross-reacts with similar tissues to MT1. Cabecadas and Isaacson found that both 
UCHL1 and MT1 have reactivity with a high percentage of T-cell lymphomas (94 and 
86%, respectively), but lacked absolute specificity for T cells, especially in high-grade 
lymphomas. CD3 was the most specific of the three T-cell markers, but stained only 
78.5% of cases in their study. In all of the CD3-negative cases, except for one 
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anaplastic large cell lymphoma of the skin, UCHL1 was also positive. This suggests 
that a panel of T-cell markers including the key reagents UCHL1 and CD3 should be 
used as part of the routine diagnostic practice for any lymphoid neoplasm.  
In our research, which is non-diagnostic, CD3 alone was used as a T-cell marker 
to find the expression in the synovial tissue.  
 
2.5.4.2 CD20 
 
A lot of attention has focused on lymphocyte development and function in the 
last 50 years, which has led to a better understanding of their function and how to 
create therapeutic agents that could cure diseases like lymphomas. The basic 
function of B and T lymphocytes is antibody production and cell-mediated immune 
response. It is interesting to know that the discovery of a B cell originated after 
identification of a protein (Ig or antibody). It is the recognition of these proteins that 
led to the discovery of the antibody-producing cell (Tiselius and Kabat, 1938). 
The molecular architecture of the B-cell surface was unknown until 
approximately 1980s and was known to consist of membrane-bound Ig, complement 
component receptors and Fc receptors. The understanding of the B-cell structure 
evolved following the advent of monoclonal antibody technology.  
B cells are important in the adaptive immune system. In addition to the 
production of antibodies, they regulate other functions to maintain immune system 
homeostasis. They produce immunomodulatory cytokines, which have effects on 
other inflammatory cells like T-cells, DCs, and antigen-presenting cells, regulate 
lymphoid tissue organisation and neogenesis, regulate wound healing and 
transplanted tissue rejection, and influence tumour development and tumour 
immunity. Moreover, B cells are required to initiate the T-cell immune response 
(LeBien and Tedder, 2008).  
 
The first specific surface antigen to be categorised was B1, now known as CD20 
(Stashenko et al., 1980). Tedder et al. (Tedder et al., 1988) analysed the B1 (CD20) 
molecule and noted that it is a phosphoprotein on the surface of human B-
lymphocytes. They also found that a predominant species of Mr 33,000 represents 
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75–80% of the iodinated cell surface B1 and a Mr 35,000 species represents 20–25%. 
CD20 is a general B-cell marker that is expressed during B-cell differentiation from 
the pro-B cell phase until the plasma cell stadium (Boross and Leusen, 2012). It is an 
activated-glycosylated phosphoprotein expressed on the surface of all B cells 
beginning at the pro-B phase and progressively increasing in concentration until 
maturity. In humans, CD20 is encoded by the MS4A1 gene. This gene encodes a 
member of the membrane-spanning 4A gene family, which encodes a B-lymphocyte 
surface molecule, which plays a role in the development and differentiation of B cells 
into plasma cells. The exact function of CD20 is still unknown. However, it is believed 
to have a role in B-cell activation, regulation of B-cell growth and transmembrane 
calcium flux (Riley and Sliwkowski, 2000).  
 
CD20 was first used as a therapeutic target in the management of lymphomas. 
CD20 monoclonal antibody (MoAb) binds to the human CD20 antigen, inducing 
CD20+ B-cell depletion. Rituximab was the first anti-CD20 MoAb to be approved by 
FDA for the management of lymphoma. Once bound to the CD20+ cells, MoAb 
causes cell depletion through three main killing pathways: complement-dependent 
cytotoxicity, antibody-dependent cell-mediated cytotoxicity and direct pro-tumour 
activity (Avivi et al., 2013). One of the B-cell functions is antibody production, which 
is important to control in autoimmune disorders like rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE). Therefore, rituximab is used to control 
autoantibody production by B-cell depletion and hence control the autoimmunity 
problem.  
This marker was included in this study to provide a complete assessment of the 
synovium in this group of patients and to see if they show any signs that suggest 
similarities to RA. 
 2.6 Rationale of the study 
 
It is still not clear why some people develop OA very late in their life while others 
get it early. The literature review suggests synovitis and inflammation as major 
contributors to OA. Increased fat in the synovial membrane will promote chronic 
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inflammation, which leads to neo-angiogenesis to maintain the metabolic demands 
of the adipocytes. This, in turn, will lead to more inflammatory cell infiltration and 
increased inflammation, which is accompanied by damage of the surrounding 
tissues, leading to early arthritis. Moreover, the synovium of obese people has not 
been studied properly before. This laboratory research will focus on comparing 
obese patients’ synovium to that of lean people of different age groups and BMIs. 
There are several questions that are of interest to musculoskeletal scientists when it 
comes to OA. This research will focus mainly on the angiogenesis and 
microcirculation of the synovium based on age and BMI.  
It is a complex study in terms of population differences and heterogeneity. OA 
itself makes it a challenging project owing to the multiple risk factors. This study has 
several limiting factors that could affect the results and interpretation. They will be 
discussed in the study limitations section (section 5.6). 
2.7 The proposed study 
 
All patients with advanced primary OA who have been assessed by clinicians and 
were eligible for primary knee arthroplasty will be categorised according to their age 
and BMI into three groups as follows:  
 
- Group 1: The young (<60) and obese (BMI > 30),  
- Group 2: The young (<60) and lean (BMI < 30)  
- Group 3: The old (>70) and lean (BMI < 30)  
 
These groups have been chosen to see differences among different age groups in 
relation to their BMI. We understand that we are not comparing like with like and 
the groups are completely different. This was discussed prior to commencing this 
project. The synovium of obese people has not been studied properly before. To 
help balance out the big differences between the old lean and young obese groups, a 
third group was recruited that shares some common features. This group was young 
and lean.  
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One of the points of interest to us is, would there be a significant difference that 
suggests the early OA in obese patients compared to the old lean patients who 
present OA late. The lean young group was added to see why this particular group 
gets early OA despite the absence of obesity as a risk factor. This group will also help 
to avoid any incorrect interpretation.  
 
The synovium was studied by looking at the histology slides after staining with 
Hematoxylin and Eosin (H&E) and IHC. The IHC was carried out to see the cells of 
interest, including endothelial cells, macrophages, fibroblasts, and B and T cells. 
 
 The histology slides were studied for: 
1- The dimensions of adipocytes (H&E only). 
2- Angiogenesis and its relation to the adipocyte size and site.  
3- Presence or absence of synovitis and scoring the synovitis, if present. 
 
 Immunohistochemistry staining was used to identify and count endothelial cells, 
fibroblasts, lymphocytes and macrophages using the following phenotypic 
markers: 
– Endothelial: vWF, CD34  
– Macrophages: CD68  
– Fibroblasts: vimentin 
– Lymphocytes: CD3, CD20 
 
2.8 Aims 
2.8.1 Primary aim 
 
To study the effect of obesity on synovial tissue as a source of chronic 
inflammation, angiogenesis and synovitis leading to the development of OA. 
 
2.8.2 Secondary aims 
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1- To study the effect of fat in the synovial tissue and it relation to 
angiogenesis. 
2- To assess the changes in microcirculation in the synovium. 
3- To explore the relation between vascular changes and other 
inflammatory cells. 
4- To determine the predominant inflammatory cell type in all the three 
groups. 
5- To assess the synovitis in all the groups. 
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3. MATERIALS AND METHODS  
 
3.1 Hypotheses 
 
Vascular and inflammatory components of synovial tissue, debrided at primary 
knee arthroplasty for OA, will vary with age and BMI. The increased fat leads to neo-
angiogenesis and hence inflammation, which causes the early onset of OA.  
 
3.2 Null hypothesis 
 
The hypotheses are individually or collectively not true  
 
3.3 Study population recruitment  
3.3.1 Study participants 
 
All patients presenting to Royal Liverpool and Broadgreen University Hospital 
NHS trust with established primary knee osteoarthritis who were indicated for total 
knee arthroplasty were eligible for the study. 
3.3.2 Inclusion criteria 
 Patient was willing and able to give informed consent for participation in 
the study. 
 Age > 70 with BMI < 30. 
 Age < 60 with BMI > 30. 
 Age < 60 with BMI < 30. 
 Diagnosed with idiopathic OA. 
 Undergoing primary knee arthroplasty for advanced end-stage OA. 
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3.3.3 Exclusion criteria 
Patients were excluded from the study if ANY of the following applied: 
 Evidence of lower limb gangrene/ulcers or peripheral vascular disease. 
 History of hepatic or renal impairment or dialysis. 
 Currently receiving or has received radiation or chemotherapy within the 
last 3 months. 
 Had inadequate venous access for drawing blood. 
 Prior or current use of systemic cortisone. 
 Any other significant disease or disorder that, in the opinion of the 
investigator, might either put the participants at risk because of 
participation in the study, or influence the result of the study or the 
patient’s ability to participate in the study. 
 Lack the capacity to give consent. 
 Secondary OA, such as inflammatory or post traumatic arthritis. 
3.3.4 The number of participants 
This study focuses on angiogenesis in relation to the fat cells in the synovium in 
patients with primary OA in different age groups and BMIs. The Von Willibrand 
Factor (vWF) is the main marker of interest to detect new endothelial cell formation. 
The literature shows that vWF is a very sensitive marker in detecting angiogenesis 
(Pessler et al., 2008a, Pessler et al., 2008b, Mucke et al., 2016). The process of 
releasing the vWF during angiogenesis has been studied by (Babich et al., 2008). 
Other factors of interest in this study are CD3, CD20, CD34, CD68 and vimentin. 
 
G*Power software was used to estimate the sample size using the previous 
findings of (Pessler et al., 2008b). This paper showed that the mean vWF level in 
normal individuals was 61.5 with a standard error of the mean (SEM) of 3.7, 
compared with 85.9 (5.9) and 85.4 (7.2) for orthopaedic arthropathies and 
osteoarthritis, respectively. The standard deviation (SD) of the control group was 
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calculated from the data available (SD = 11.7). The details of Pessler’s statistical 
analysis are shown in Table 3.1. RA was excluded from the analysis as it is not in the 
scope of this study. In this project, we are examining three different groups, which 
are most likely not normally distributed. Thus, an ANOVA fixed effect one way test 
was used. The data was plotted in G*Power using the ANOVA fixed effect one way 
test to determine the sample size and the power of the study.  
With a power of 85% and alpha error of 0.05, five patients are required in each 
group to produce a statistical significance for the vWF level. The same test was run 
to assess the power when using five patients in each group for the other factors of 
interest (CD20, CD3, CD68). CD20 and CD68 will be well powered (over 99%) when 
using five patients. On the other hand, CD3 would be underpowered. 
 
Table 3.1: Data of synovial markers from Pessler et al. 
 
 
 
3.3.5 Participant recruitment to the LMB 
 
A member of the local clinical or research team within the LMB identified 
participants with established knee arthritis presenting to the outpatient 
trauma/orthopaedic clinic or on admission for surgery. The eligibility criteria were 
checked and those patients potentially suitable for inclusion were given information 
about the LMB and invited to discuss the role of the LMB further with a member of 
52 | P a g e  
 
the research team. Those who were willing to participate were given the opportunity 
to ask questions and the appropriate informed consent was obtained. All routine 
patient care followed good clinical practice guidelines. Once consent was signed, 
participants were recruited in the LMB and baseline outcome data were collected in 
the outpatient clinic. 
 
 
3.3.6 Sample collection 
For those patients undergoing knee arthroplasty, tissues were collected as per 
the LMB protocol. The surgeon who performed the procedure took the samples 
from the suprapatellar pouch and medial and lateral gutters. The samples were then 
sent to the LMB for storage as explained in the sample handing section. The stored 
synovium was accessed through the LMB for analysis according to the study 
protocol. Tissue samples were used for histology and immunohistochemistry. 
 
3.3.7 Sample handling  
Tissue samples were placed in containers containing RNAlater or formalin and 
were prepared for dispatch, including anonymising the sample using the 
participant’s unique study number, initials, date and time. A good clinical practice 
(GCP)-trained research nurse or fellow transported the samples to the LMB. Samples 
were divided into adequate sizes and allocated for the study investigations. Only 
those involved in the research process had access to the samples. 
 
3.3.8 Blinded assessors procedure 
Samples were link-anonymised and blinded using the participant’s unique study 
number. The assessor of the samples in this case had to know the details of the 
patients to make sure they satisfied the inclusion and exclusion criteria. Information 
on patient age and BMI were essential to allocate the patient to the correct group 
and to make sure that the number of participants in each group was similar. Blinding 
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was done at the time of assessment of the IHC slides. This was to ensure assessor 
blinding to reduce bias. However, there were situations where the assessment was 
not blinded to look at hot spots (areas with severe inflammation or synovitis) in the 
whole slide, which was difficult to blind. 
 
 
3.3.9 Discontinuation/withdrawal of participants  
 
Each participant had the right to withdraw from the study at any time. The 
research team would record any reason for any withdrawal on the study Withdrawal 
CRF and the participant would be asked if the study team might use the data 
collected up to the point of withdrawal.  
 
3.3.10 Ethics approval 
 
Ethical approval was obtained by the chief investigator for sample collection to 
go to the Liverpool Musculoskeletal Biobank (REC reference number 15/NW/0661 
dated 9th September 2015). The study was carried out under the supervision of the 
research team outlined above after obtaining sponsorship from the University of 
Liverpool. 
 
3.3.11 Role of Liverpool Musculoskeletal Biobank (LMB) 
 
LMB is an HTA (Human Tissue Authority)-approved research biobank under 
ethical approval of the central Liverpool ethics committee (reference 15/NW/0661). 
The LMB sponsor is the University of Liverpool (reference UOL001150) operating 
under HTA license reference 12020. The LMB staff are responsible for obtaining 
consent from participants, collection of tissues and data, samples logging, sample 
tracking, and storage and disposal of samples as per LMB-approved standard 
operating procedures. The samples were accessed through the LMB after obtaining 
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sponsorship from the University of Liverpool and getting approval to start recruiting 
the patients (reference: UOL001283). 
 
3.4 The Laboratory work 
The groups were allocated as follows (Figure 3.1):  
Group 1: Young obese (six patients) 
Group 2: Young lean (five patients) 
Group 3: Old lean (six patients) 
 
 
 
 
Figure 3. 1 : Study population (see Appendix 1 for the study flowchart). 
  
The tissue samples were collected from the LMB stored in paraffin blocks. The 
patient samples were allocated to the specific groups based on age and BMI after 
satisfying the inclusion and exclusion criteria. The paraffin blocks were amalgamated 
in such a way that each group was in one composite paraffin block. This idea was to 
Primary total knee 
replacement for 
advanced primary OA
<60 Years (BMI>30)
6 Synovial samples 
male or female
H&E+ IHC
<60 Years (BMI<30)
5 Synovial samples 
male or female 
H&E+ IHC
>70 Years (BMI<30)
6 Synovial samples 
male or female
H&E+ IHC
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reduce the time and cost involved in block sectioning and staining. It also helped 
reduce the number of slides for each marker, which helped during IHC staining to 
apply the same treatment across all the groups without any discrepancy in time. 
After the power calculation, the total number of patients recruited was 17. Tonsil 
tissue was used as a positive control and was placed in the group 2 composite block. 
The block designs are shown in Figure 3.2. 
 
Group 1  
(Young obese) 
 
Patient 038 Patient 020  
 Patient 068  
Patient 080 Patient 050 Patient 057 
 
Group 2  
(Young lean) 
Patient 028 Patient 071  
 Patient 070  
Patient 069 Tonsil tissue Patient 041 
 
Group 3   
(Old lean) 
Patient 023 Patient 072  
 Patient 030  
Patient 019 Patient 033 Patient 052 
 
Figure 3. 2: Map of patient location in the composite block and the histology slides in all the groups. 
 
The patient tissues were arranged in the composite block in this irregular way to 
avoid mixing the samples up when sectioning and fixing the tissue to the slides. This 
was to allow the investigator to know which patient is at which position based on 
the map provided in Figure 3.2. 
 
After sectioning the blocks, H&E staining was done followed by the IHC staining 
for the following markers: CD3, CD20, CD34, CD68, vWF and vimentin. Table 3.2 
details the type of antibody and titration. 
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Table 3.2: Antibodies used for immunohistochemistry. 
Primary 
antibody 
Source Isotype Clone Dilution Treatment Linker 
vWF DAKO  
Polyclonal 
rabbit 
1:1000 High PH 
Rabbit 
linker 
CD 34 DAKO IgG1 
Monoclonal 
mouse 
(class 2 
QBEnd 10) 
1:50 High PH 
Mouse 
linker 
CD 3 DAKO IgG3 
Monoclonal 
mouse 
Ready to 
use 
High PH None 
CD 20 DAKO IgG3 
Monoclonal 
mouse 
Ready to 
use 
High PH None 
CD 68 DAKO IgG3 
Monoclonal 
mouse (PG-
M1) 
1:600 High PH None 
Vimentin DAKO IgG2a 
Monoclonal 
mouse (V9) 
1:200 High PH None 
 
 
The H&E staining was done by the Liverpool Bio-Innovation Hub Biobank, where 
they use an automated H&E staining machine (Leica Autostainer).  
 
The IHC staining was carried out using the autostainer as follows: 
 
 Envision-Flex block was incubated at room temperature for 5 
minutes. 
 Primary antibody incubated for 30 minutes after dilution to 
appropriate concentration using antibody diluent (Envision-
Flex). 
 Appropriate linker as outlined in Table 1.2 (i.e. mouse for 
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mouse primary antibody) was added and incubated at room 
temperature for 15 minutes. 
 HRP was added and incubated at room temperature for 20 
minutes. 
 DAB added and incubated at room temperature for 20 
minutes.  
 The slides were unloaded from the autostainer and 
transferred into a dH2O bath. 
 Counterstaining with haematoxylin solution was done for 1 min.  
 The slides were then dipped in acidic alcohol and rinsed in tap 
water 
 Next, the slides were dipped in ammonia water for 30 sec and 
rinsed in tap water before returning to the bath of dH2O. 
 The slides were dehydrated through five changes of industrial 
methylated spirits and two changes of xylene in a fume hood. 
 Finally, the slides were mounted in DPX.  
 
These markers had already been worked up in the Royal Liverpool and 
Broadgreen University Hospital NHS Trust laboratory and similar markers were used 
in this project with the same dilution as outlined in the table 3.2. 
 
An autostainer was used to insure that all the slides received similar treatment 
and to avoid any potential human error. The positive control was a tonsil tissue. The 
negative control was the patients’ own tissues but without the antibody treatment. 
This was done to eliminate any non-specific staining that could affect the results. The 
positive control showed good uptake of all the markers. The negative control did not 
show any non-specific uptake. A trained person supervised the staining procedure to 
ensure that all the steps were carried out correctly. The details of the staining 
procedure are shown in Appendix 2.  
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The slides were examined for staining quality by the supervisor. The staining was 
satisfactory and there was no need to repeat any markers. Subsequently, the slides 
were scanned using an APERIO IMAGE SCANNER and the slides were ready to be 
analysed. The images were opened using ImageScope software. Multiple images 
were taken at ×10 magnification to cover the whole slide for each marker. The 
images were divided into either synovial or fat based on the major tissue. The 
images were labelled as synovium if >50% of the specimen was synovial tissue with 
cells and stroma and fat if >50% of the tissue was fat. So, each slide would have fatty 
and synovial sections.  
3.4.1 Immunohistochemistry      
 
Immunohistochemistry (IHC) is a powerful method for localising specific antigens 
in formalin-fixed, paraffin-embedded (FFPE) tissues based on antigen–antibody 
interactions (Taylor and Burns, 1974). It relies on antigen–antibody interactions to 
identify cellular or tissue constituents. The site of antibody binding is identified by 
direct labelling of the antibody, or by use of a secondary labelling method (Bancroft 
JD, 2008). IHC is a well-established technique (Figure 2.2). 
 
 
Figure 2. 3: diagram showing how IHC works (adapted from Prestige Antibodies) 
There are essential steps that must be carried out before staining, including 
tissue fixation. It is important to preserve the tissue from changes that may affect 
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the cellular and extracellular components. Formalin is widely used for this purpose. 
Although formalin is very good at fixing the tissue, it has some unwanted effects like 
crosslinking between proteins themselves and proteins with nucleic acids. It also can 
mask or damage epitopes through alteration of the protein’s dimensional structure. 
The fixed tissues then go through a process of embedding in paraffin blocks. This 
process involves alcohol treatment followed by xylene, and then embedding in the 
paraffin block before storage.  
 
 
IHC involves the following steps: 
3.4.1.1 Sectioning 
 
The FFPE tissue is sectioned into slices of 4–5 µm thickness and mounted on a 
slide. 
3.4.1.2 Antigen retrieval 
 
The paraffin must be completely removed from the FFPE sections for the 
antibodies to reach the target antigens (antigen retrieval). There are different 
antigen retrieval methods available. Heat-induced epitope retrieval using the Dako 
PT-Link with high pH was used in this project. The protocol for PT-Link antigen 
retrieval is included in the appendix 2. 
3.4.1.3 Blocking endogenous target activity 
 
Peroxidases, most often horseradish peroxidase (HRP), are commonly used as 
the reporter for target antigen detection by IHC. Final analysis of this staining 
method is complicated by the presence of endogenous peroxidase and 
“pseudoperoxidase” activity in the cells and tissues. Endogenous peroxidase reacts 
with hydrogen peroxide to reduce the 3,3'-diaminobenzidine (DAB) substrate or 
other peroxidase substrates, resulting in nonspecific staining of the tissue. To 
prevent false positive and high background detection of the stain, blocking of 
endogenous forms of peroxidases or phosphatases is important. A commercially 
available chemical blocking agent was used (Dako Envision-Flex block, Dako UK Ltd.).  
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3.4.1.4 Immunodetection 
 
IHC target antigens are detected through either chromogenic or fluorescent 
means. Chromogenic detection is based on the activities of enzymes, most often HRP 
or alkaline phosphatase, which form coloured, insoluble precipitates upon the 
addition of the substrate, such as DAB and nitro blue tetrazolium (NBT)/5-bromo-4-
chloro-3-indolyl phosphate (BCIP), respectively. HRP (Dako UK Ltd) was used for this 
step. 
 
3.4.1.5 Sealing the stained sample 
 
Once the staining procedure is done, the slide is sealed by mounting a coverslip 
with an appropriate mountant to stabilise the tissue sample and stain. This allows 
preservation of the sample for long-term use and storage. 
3.4.1.6 Controls 
 
Controls are used to validate IHC results. 
      a) Positive control 
 
This is a tissue that is known to contain the antigen of interest detected by 
identical IHC methods to those used in diagnostic cases. Positive tissue controls must 
be fixed and stained in the same way as the diagnostic case tissue for every antibody 
and procedure used (José A. Ramos-Vara, 2008). Tonsil tissue was used as the 
positive control in this work.  
   b) Negative controls 
 
The same tissue can be used but the primary antibody is omitted from the 
staining schedule. It is replaced by an immunoglobulin, which is directed against an 
unrelated antigen. Commonly, the primary antibody is replaced by antibody diluent, 
same species non-immune immunoglobulin of the same dilution and 
immunoglobulin concentration, an irrelevant antibody or buffer. These methods will 
assess the degree of cross-reactivity of the primary antibody and the degree of 
nonspecific binding by the labelling (secondary) antibody and detection system. In 
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this project, we used the patient’s tissue samples as a negative control to detect any 
non-specific staining.  
The IHC staining protocol that was used in this was adapted from the Liverpool 
Ocular Oncology Research Group (Appendix 2). 
 
3.4.2 IHC analysis and assessment 
 
Image analysis was done using ImageJ software (version Fiji-win64). The markers 
were quantified as percentage of stain following Dr. Ashish N. DebRoy (N, 2012) 
technique using ImageJ software (N, 2012). The same technique was also used by 
Mucke (Mucke et al., 2016) and colleagues for assessment of inflammation in the 
synovium (Mucke et al., 2016). The technique relies on choosing the colour 
deconvolution that represents DAB, then the threshold is readjusted for every 
marker separately to get rid of the background noise. After that, H DAB vector is 
used to isolate the DAB stain. The software then measures the total DAB percentage, 
which is related to the specific tissue, based on the antibody used.  
 
3.4.2.1 Blinding 
 
The images were blinded by the supervisor using the ImageJ software to ensure 
that bias was eliminated while doing the assessment. Each marker for all the groups 
was saved in a separate folder to allow access and specific threshold while using 
ImageJ. The author was blinded and did not know which image was related to which 
patient until all the measurements were taken. After the completion of the ImageJ 
quantitative measurements, the blinding was removed. Blinding was done for the 
ImageJ analysis only. 
 
3.4.2.2 Quantitative measurements using ImageJ software 
 
ImageJ software was used to quantify the percentage of stained cells in the 
whole slide. A threshold was measured for each stain to detect the DAB marker. It 
relies on the percentage of the stained cells in a given area. The DAB percentage was 
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measured in the whole slide for each marker. Each marker was assessed with a 
specific threshold to avoid counting any background noise in the image. The DAB 
percentage of each image was recorded. Both the synovial and fatty sections were 
analyzed.  
 
3.4.3 Other manual measurements 
 
3.4.3.1 Vascular density in the intimal layer of the synovium 
 
Vascular density was used to count the vessels in the hot spots. A hot spot was 
defined as the area with the highest number of vessels and inflammatory cell 
infiltration in the intimal layer of the synovium. Only fields with clearly recognizable 
intimal and subintimal vasculature were included (Pessler et al., 2008a). This 
calculation was done at ×10 magnification using the vWF as a marker of endothelial 
cells. The number of vessels in the power field was counted (Pessler et al., 2008a). 
The vascular density was further divided into vessels that had a smooth muscle layer 
and those that did not have any smooth muscle layer. The vessels that had a smooth 
muscle layer represented the arterioles whereas those that did not have a smooth 
muscle layer represented the capillaries. 
 
3.4.3.2 Vascular density in the fat sections 
 
The same technique of vascular density measurement was done in the fat 
sections. The areas were chosen in places where only fat cells were present and the 
sections were not distorted. Only the number of vessels present in the power field 
was counted. There was no further division of vessels with or without smooth 
muscle layer.  
 
3.4.3.3 Vascular wall thickness 
 
The slides were examined for vascular hyperplasia. The worst section was chosen 
from each slide at ×10 magnification where a collection of vessels with vascular wall 
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hyperplasia was present. These vessels were chosen to be very close to the synovial 
intima to avoid deeper sections were the vessel can be bigger in size normally. The 
mean vascular wall thickness was measured in these areas. The thickness was 
measured from the inner surface of the vascular lumen (tunica intima) to the outer 
surface of the tunica media, which is also known as the intima–media thickness 
(IMT). IMT is an indicator of subclinical atherosclerosis that gives an assessment of 
cardiovascular disease risk and is usually measured in the carotid by ultrasound scan 
(Stein et al., 2008, Han et al., 2016). This was examined in vessels very close to the 
synovial intimal and sub-intimal layers. The slide was not included if there was no 
representative section of the synovium.  
 
3.4.3.4 Vessel distance from the joint-facing synovial surface 
 
The distance of the nearest vessel to the joint-facing synovial surface was 
measured in the same palaces where the vascular density was measured. The 
measurement was taken at magnification of ×10. The average was taken for the 
distance (Levick, 1995). 
 
3.4.3.5 Fat cell diameter  
 
To assess the fat cell size, ideally adipocytes should be isolated by collagenase 
digestion (Fang et al., 2015). However, in this project we relied on H&E staining for 
assessment of fat cell size. This measurement was used to assess the local fat burden 
as a tool of the local effect of obesity. The diameters of the fat cells were measured 
from different places in each slide where the fat cells were intact and the wall was 
clear with no signs of disruption of the tissue. This was done manually in 
micrometres using the image scope software measurement tools. The H&E-stained 
slides were used for this measurement. The average was calculated and plotted on 
the data sheet. The measurement followed (Fernandes-Santos et al., 2009) fat cell 
diameter method. 
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3.4.4 Semi-quantitative assessment 
 
Semi-quantitative assessment of the number of the stained cells was done 
following Dr Parashar and Professor Helliwell’s (Parashar; and Helliwell, 2012 ) 
method of assessment on the synovium(Parashar; and Helliwell, 2012 ). Cell 
expression was categorised based on the number of stained cells in the histology 
slide. It was classified as no expression (0), few positive cells (1+) and many positive 
cells (2+). The positive and negative tissue samples were used as a baseline from 
which to determine the strength of the expression. Table 3.3 shows the simple 
description of the semi-quantitative assessment. 
 
Table 3.3: Description of semi-quantitative scoring system  
Score Description  
0 No expression 
1+ Few positive cells 
2+ Many positive cells  
 
3.4.5 Chronic synovitis scoring 
 
The H&E-stained histology slides were evaluated for the presence or absence of 
chronic synovitis using Krenn et al.’s (Krenn et al., 2006)scoring system (Krenn et al., 
2006). Table 3.4 outlines the components of the scoring system 
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Table 3.4: Chronic synovitis scoring system (Krenn et al., 2006). 
 
Enlargement of the synovial lining cell layer 
0 points 
 
The lining cells form one layer. 
1 point The lining cells form 2–3 layers. 
2 points The lining cells form 4–5 layers, few 
multinucleated cells might occur. 
3 points The lining cells form more than 5 layers, 
the lining might be ulcerated and 
multinucleated cells might occur. 
Density of the resident cells 
1 point 
 
The cellularity is slightly increased. 
2 points The cellularity is moderately increased, 
multinucleated cells might occur. 
3 points The cellularity is greatly increased, 
multinucleated giant cells, pannus 
formation and rheumatoid granulomas 
might occur. 
Inflammatory infiltrate 
0 points 
 
No inflammatory infiltrate. 
2 point 
 
Numerous lymphocytes or plasma cells, 
sometimes forming follicle-like 
aggregates. 
3 points 
 
Dense band-like inflammatory infiltrate 
or numerous large follicle-like 
aggregates. 
Sum 0–1 
 
No synovitis 
Sum 2–4 
 
Low-grade synovitis 
Sum 5–9 
 
High-grade synovitis 
 
3.5 Statistics and analysis 
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Variables collected were subjected to normality test using the Shapiro–Wilk test. 
Parametric data were described as mean ± standard deviation whilst non-parametric 
data were reported as median with ranges. With regards to categorical data, they 
were explained in percentages. 
 
The sample size is small and the data is non parametric. Thus, for comparison of 
more than groups the Kruskal–Wallis test was used and the Mann–Whitney U test 
was used for two groups. The Spearman test was used to assess correlations 
between variables.  
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4. RESULTS 
4.1 Demographics 
4.1.1 Age and BMI 
 
A total of 17 patients were recruited to this study and divided into three groups. 
Group 1 represented the young obese patients. Six patients were allocated to group 
1 with a mean (SD) age of 53.3 (2.33) and BMI of 38.53 (1.16). Group 2 had five 
patients with a mean (SD) age of 55.60 (2.33) and BMI of 27.01 (1.59), and six 
patients were allocated to group 3 with a mean (SD) age of 75.33 (3.2) and a BMI of 
25.64 (2.5).  
 
The Shapiro–Wilk test was used to assess the normality of the age and BMI data 
and it was not normally distributed. Across-groups comparison was done using the 
Kruskal–Wallis test and the data showed a significant difference across the groups 
for both age and BMI. There was no significant difference in the ages between 
groups 1 and 2. Group 3 was significantly different when compared to group 1 (P = 
0.02). On the other hand, BMI was significantly different between groups 1 and 2 as 
well as groups 1 and 3, with P values of 0.043 and 0.004, respectively. This shows 
that groups 1 and 2 are matched for age (<60) whereas groups 2 and 3 are matched 
for BMI (<30). Table 4.1 shows the details of the statistics.  
 
Table 4.1: Group distribution according to age and BMI 
Groups (N = 17) P value 
 Young Obese (G1, n = 6)  
(Age < 60, BMI > 30) 
Young Lean (G2, n = 5) 
(Age < 60, BMI < 30) 
Old Lean (G3, n = 6) 
(Age >70, BMI < 30) 
 
 Mean   Median   Range   SD 
 
Mean   Median   Range   SD 
 
Mean   Median   Range   SD 
 
 
 
Age 
53.3     54.00     (49–55)   2.33 55.60   58.00   (48–59)   4.50 75.33     74.50     (71–80)   3.2 Across all groups :  
p= 0.02 a 
G1 = G2 : p =1.00 b 
G1 < G3 : p = 0.02 b 
G2 < G3 : p = 0.063 b 
BMI 38.53 38.41  (36.8–40.2) 1.16 27.01  26.74 (25.7–29.3) 1.59  25.64  25.39  (22.4–40.3)  2.5 Across all groups :  
p= 0.03 a 
G1 > G2 : p =0.043 b 
G1 > G3 : p = 0.004 b 
G2 < G3 : p = 1.00 b 
Note. a = Kruskall–Wallis test.  b = Dunn–Bonferroni post hoc test.  
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Figures 4.1 and 4.2 present the medians of each group and show how they are 
distributed.  
 
  
           Figure 4. 1: Age distribution                       Figure 4. 2: BMI distribution 
 
4.1.2 Other clinical data 
 
Other parameters were also obtained through the LMB database. The data 
obtained included: gender, smoking status, ASA grade, comorbidities, Kellgren and 
Lawrence (KL) score, metabolic syndrome, use of statins and non-steroidal anti-
inflammatory drugs (NSAIDs), number of painful joints, WOMAC score and SF12 
score. As shown in Table 4.2, the male to female ratio is almost similar in group 1 
and 2 but in group 3 there is more female than male representation (F:M = 2:1).   
 
    There were more smokers in group 2 than in the rest of the groups. The project 
population showed good general health and the overwhelming majority were ASA 
grade 2. All three groups had few comorbidities. Approximately half of group 1 and 2 
suffered with one comorbidity. On the other hand, the majority of group 3 patients 
were healthy. No patients fulfilled the criteria of metabolic syndrome. In addition, 
none of the patients were using lipid-lowering medications (statins). A few patients 
from group 1 and 2 were using NSAIDs. However, all the patients in all the groups 
shared the same advanced OA score (KL score). The average number of painful joints 
in each group was three. They did not show any significant differences in their 
functional scores including WOMAC and SF12. Although smoking is more common in 
group 2, comparison of the smokers and non-smokers did not show any significant 
differences in the distribution of the IHC markers when using the Mann–Whitney U 
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test. 
 
Table 4.2: Other clinical parameters (*= see appendix 4, **= see appendix 3) 
Groups (N=17) 
 
 
Young Obese (G1, =6) 
(Age<60, BMI>30) 
Young Lean (G2, n = 5) 
(Age<60, BMI<30) 
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
Sex  
 M 
 F 
 
3 
3 
 
2 
3 
 
2 
4 
Smoking  
 Yes 
 No 
 
1 
5 
 
4 
1 
 
1 
5 
ASA  
 1 
 2 
 3 
 4 
 5 
 
0 
5 
1 
0 
0 
 
1 
3 
0 
0 
0 
 
0 
6 
0 
0 
0 
Comorbidities 
 Yes 
  
 No  
 
  3 (1 in each affected 
             patient) 
3 
 
3 (1 in each affected 
patient) 
2 
 
 2 (1 in each affected  
             patient) 
4 
KL score 
 1  
 2 
 3 
 4  
 
0 
0 
0 
6 
 
0 
0 
0 
 6 
 
0 
0 
0 
6 
MetS  
 Yes 
 No 
 
0 
6 
 
N/A 
 
N/A 
Statins  
 Yes 
 No 
 
0 
6 
 
0 
5 
 
0 
6 
NSAIDs  
 Yes 
 No 
 
 2 
 4 
 
 1 
4 
 
 0 
6 
No. of painful 
joints (average) 
3 3 3 
WOMAC score* 
(average) 
81 68 67 
SF 12** 
(average)  
 PCS 
MCS 
 
 
22.35 
49.45 
 
 
31.99 
54.932 
 
 
29.54 
50.91 
 
4.1.3 Summary of demographic data 
 
The project population was chosen carefully to avoid any factors that could affect the 
results. They are almost similar except for the age and BMI. They are all at the same stage of 
advanced knee arthritis with no significant difference in their functional scoring. The 
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comorbidities were evenly distributed and this was reflected in the ASA score. Although 
group 2 had more smokers compared to the other groups, no significant differences were 
observed in the distribution of markers among the smokers and non-smokers. Of course, the 
sample size is too small to confirm the effect of smoking on the markers.  
4.2 H&E stain analysis 
The synovial samples were heterogeneous with the sections varying in size and 
tissue components. Some samples showed pure cellular and stromal components 
whilst others showed a mixture of fatty and cellular components. The ratio of the 
pure synovial cellular sections to the fatty sections was also variable. The fat 
representation was variable among patients. There were also differences in the 
synovitis and inflammatory infiltrations. The fat cells in some sections were 
distorted. All these differences were assessed systematically in the following 
sections. Figure 4.3 shows examples of H&E-stained sections taken at ×5 
magnification for patients from different groups. 
 
There were some interesting findings in the morphology of the microvasculature 
of the synovium where vascular hyperplasia was observed in the synovial sections. 
They were more pronounced in the young obese people.  
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Figure 4. 3: young obese patient sample showing a florid synovitis with significant 
inflammatory cells infiltrations (A), another young obese patient showing a mix of fat and 
cellular components and also demonstrate synovitis (B), young lean patient showing 
evidence of synovitis(C), old lean patient with no evidence of synovitis(D). 
A 
B 
C 
D 
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4.3 Comparison of stain surface area 
4.3.1 vWF 
 
 
The DAB percentage was measured using ImageJ software as outlined in the 
methodology section (section 3.9.1.2). The vWF was measured in the synovial tissue 
and the fatty tissue for the whole slide section for each patient. The data were 
tested for normality and were found to be not normally distributed (Shapiro–Wilk 
test < 0.05). The Kruskall–Wallis test showed a significant difference across the 
groups in the synovial tissue. The significant values were readjusted using Dunn–
Bonferroni post hoc analysis, which showed that the actual difference arises 
between group 3 and 1. On the other hand, the fatty tissue did not show statistical 
difference. Furthermore, the total (i.e. synovium and fat) percentage of vWF did not 
show any statistical difference. Although there was no statistical difference, there is 
a trend towards increased percentage in group 3 followed by group 2 and 1 (Table 
4.3 and Figure 4.5). The same statistical procedures were applied to the other 
markers.  
 
The measurement of vascularity using ImageJ software may not be very accurate 
because it relies on the percentage of the surface area of the vessels. The 
orientation of the vessels and the way they have been cut will affect the reading. 
This issue is demonstrated in the following IHC sections (Figure 4.4) of vWF of 
different groups. It is obvious from the slide sections that the number of actual 
vessels is greater in the obese patient’s sample but because of the vessel orientation 
and shape the readings were significant for the old people. This was reflected in the 
significant difference in the synovial section in the old age group. This significant 
difference could be attributed to one outlier in group 3. To avoid this problem, the 
actual vessel counts in the hot spots were obtained.  
 
The IHC samples of all the markers among the groups are shown in figure 4.33. 
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Figure 4. 4: The vWF expression in different groups. Young obese patient sample shows 
multiple small microvessels (A), Young lean patient sample shows multiple small microvessels 
(B). Old lean patient sample shows vessels cut longitudinally representing a very big surface 
area and the actual count is less compared to other patients (C) 
 
A 
B 
C 
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Table 4.3: Percentage of vWF stain surface area  
Groups (N=17)  P value 
 Young Obese (G1, n =6) 
(Age<60, BMI>30)  
Young Lean (G2, n = 5) 
(Age<60, BMI<30)  
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 Median (SD) 
 
Median (SD) 
 
Median (SD) 
 
 
vWF Synovium 7.04(0.58) 7.12(1.06) 8.54(4.06) Across all groups :  
p= 0.029 a 
G1 = G2 : p =0.95 b 
G1 < G3 : p = 0.024 b 
G2 < G3 : p = 0.40b 
vWF Fat 
 
7.01(0.87) 6.97(0.79) 7.71(3.60) Across all groups :  
p= 0.43a 
 
vWF Total  12.41(5.82) 14.04(1.85) 14.95(8.75) Across all groups :  
p= 0.293 a 
 
Note. a = Kruskall–Wallis test.  b = Dunn–Bonferroni post hoc test. 
 
It is important to note that group 3 had one case as an outlier, which could have 
made the difference significant. 
 
 
  
 
Figure 4.5: Percentage vWF synovial surface area. 
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Figure 4.6: Percentage CD34 total surface area. 
 
4.3.2 CD34 
 
CD34 did not show any statistically significant difference in both synovial and fat 
sections across all the groups. The CD34 total also followed a similar trend when 
compared to vWF synovium, but not exactly the same (see Figures 4.5 and 4.6). 
Table 4.4 details the CD34 statistics. The following table ( Table 4.4 ) shows examples 
the IHC staining of CD34. 
 
Table 4. 4: Examples IHC staining of CD34 
 Young Obese Young Lean Old Lean 
CD34 
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Table 4.5: Percentage of CD34 surface area  
Groups (N=17) P value 
 Young Obese (G1, n=6) 
(Age<60, BMI>30) 
Young Lean (G2, n=5) 
(Age<60, BMI<30) 
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 Median (SD) 
 
Median (SD) 
 
Median (SD) 
 
 
CD34 
Synovium 
18.07 (6.22) 21.70(9.90) 24.47(9.82) Across all groups :  
p= 0.468a 
CD34 Fat 10.31(7.58) 12.95(14.20) 16.88(11.15) Across all groups :  
p= 0.692a 
 
CD34 Total  28.74(13.03) 34.65(23.64) 34.60(16.82) Across all groups :  
p= 0.445a 
 
Note. a = Kruskall–Wallis test.   
 
4.3.3 CD68 
 
CD68 did not show any statistical difference across groups. However, group 1 
showed a greater increase in percentage when compared to the other groups with 
an increasing tendency going from group 3 towards group 1. In fact, in the fat 
section the difference is very big and very close to being significant (P = 0.059). There 
are outliers that could have made the difference not significant. The graphs in Figure 
4.7 and 4.8 show this trend very clearly. The following table (table4.6) shows the IHC 
staining of CD68. 
 
Table 4. 6: Examples of IHC staining of CD68 
 Young Obese Young Lean Old Lean 
CD68 
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Figure 4.7: Percentage of CD68 fat surface area. 
 
 
 
  
Figure 4.8: Percentage of CD68 total surface area. 
 
Table 4.5 shows the statistical details for CD68. CD68’s correlation with other 
markers, age and BMI will be analysed in the following sections. 
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Table 4.7: Percentage of CD68 stain surface area  
Groups (N=17) P value 
 Young Obese (G1, n =6) 
(Age<60, BMI>30) 
Young Lean (G2, n = 5)  
(Age<60, BMI<30) 
Old Lean (G3, n = 6)  
(Age>70, BMI<30) 
 
 Median (SD) 
 
Median (SD) 
 
Median (SD) 
 
 
CD68 
Synovium 
7.43(0.76) 7.90(0.97) 7.08(0.57) Across all groups : 
p= 0.264a 
CD68 Fat 9.10(0.99) 7.67(0.72) 6.82(0.42) Across all groups : 
p= 0.059a 
 
CD68 Total  14.71(4.83) 14.04(3.07) 9.81(3.35) Across all groups : 
p= 0.085a 
 
Note. a = Kruskall–Wallis test.   
 
 
 
 
4.3.4 CD3 
 
Although CD3 did not show any statistically significant differences across groups, 
it showed a trend of increased percentage in group 1 followed by group 2 and 3 in 
the synovial and total combined sections. The fat sections did not show any specific 
pattern. The boxplots in Figures 4.9 and 4.10 and Table 4.6 show the details of the 
results and how they are distributed. The following table (table 4.8) shows examples 
the IHC staining of CD3. 
 
Table 4. 8: Examples of IHC staining of CD3 
 Young Obese Young Lean Old Lean 
CD3 
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Figure 4.9: Percentage of CD3 synovial surface area  
 
  
Figure 4.10: Percentage of CD3 total surface area  
 
These graphs also shows that group 3 has got an outlier, which could affect the 
results. It shows the heterogeneity of the individuals even within the groups.  
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Table 4.9: Percentage of CD3 stain surface area  
Groups (N=17) P value 
 Young Obese (G1, n =6) 
(Age<60, BMI>30) 
Young Lean (G2, n = 5) 
(Age<60, BMI<30) 
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
 
CD3 
Synovium 
7.35(0.71) 7.11(0.76) 7.02((1.48) Across all groups :  
p= 0.192a 
CD3 Fat 7.19(0.95) 8.48(2.99) 6.36(0.08) Across all groups :  
p= 0.408a 
 
CD3 Total 13.10(3.80) 12.76(5.97) 9.56(3.22) Across all groups :  
p= 0.112a 
 
Note. a = Kruskall–Wallis test. 
   
4.3.5 CD20 
 
As for CD20, the across groups comparison did not show any statistically 
significant differences and there was no specific distribution pattern. However, there 
could be some hint of an increase in the synovial CD3 in the overall combined total 
sections. The details are shown in the graphs in Figures 4.11 and 4.12 and Table 4.7. 
The following table ( table 4.10) shows examples the IHC staining of CD20. 
 
Table 4. 10: Examples of IHC staining of CD20 
 Young Obese Young Lean Old Lean 
CD20 
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Figure 4.11: Percentage of CD20 synovial surface area. 
 
  
Figure 4.12: Percentage of CD20 total surface area. 
 
The same outlier problem exists again for CD20. When looking into the data in 
detail, the outlier was not the same across the groups.  
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Table 4.11: Percentage of CD20 stain surface area  
Groups (N=17) P value 
 Young Obese (G1, n =6) 
(Age<60, BMI>30) 
Young Lean (G2, n = 5) 
(Age<60, BMI<30) 
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
 
CD20 
Synovium 
8.01(1.62) 6.75(0.45) 7.48(1.72) Across all groups :  
p= 0.373a 
CD20 Fat 7.73(1.38) 7.71(1.75) 7.04(0.94) Across all groups :  
p= 0.700a 
CD20 
Total  
13.82(4.78) 9.84(4.48) 10.30(4.23) Across all groups :  
p= 0.295a 
 
Note. a = Kruskall–Wallis test. 
 
4.3.6 Vimentin 
 
Vimentin showed statistical differences across the groups in the synovial, fat and 
total sections. Table 4.8 shows this in detail. Although there is significant difference 
across the groups, this difference changed following the Dunn–Bonferroni post hoc 
test readjustment. However, it is obvious that the vimentin marker is expressed 
more in the young patients (groups 1 and 2). The following table (table 4.12) shows 
examples of the IHC staining of Vimentin. 
 
 
Table 4. 12: Examples of IHC staining of Vimentin 
 Young Obese Young Lean Old Lean 
Vim 
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Table 4.13: Percentage of vimentin stain surface area  
 Groups (N=17) P value 
 
 
Young Obese (G1, n =6) 
(Age<60, BMI>30) 
Young Lean (G2, n = 
5) (Age<60, BMI<30) 
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 Mean (SD) 
 
Mean (SD) 
 
Mean (SD) 
 
 
Vim 
Synovium 
15.40(6.21) 12.92(3.11) 6.37(0.31) Across all groups :  
p= 0.006 a 
G1 = G2 : p =1.000 b 
G1 > G3 : p = 0.013 b 
G2 > G3 : p = 0.036b 
Vim Fat 11.08(6.47) 10.55(3.13) 6.31(0.22) Across all groups :  
p= 0.029a 
G1 = G2 : p =1.000b 
G1 > G3 : p = 0.076 b 
G2 > G3 : p = 0.064b 
Vim Total  24.27(13.21) 20.84(5.75) 10.58(3.46) Across all groups :  
p= 0.029a 
G1 = G2 : p =1.000b 
G1 > G3 : p = 0.044 b 
G2 > G3 : p = 0.058b 
Note. a = Kruskall–Wallis test.  b = Dunn–Bonferroni post hoc test. 
 
 
Figures 4.13 and 4.14 show the data distribution. They also highlight outliers; similarly to 
when looking at the previous results, it is not related to a particular group or patient.  
 
  
Figure 4.13: Percentage of vimentin synovial surface area among groups.  
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Figure 4.14: Percentage of vimentin total surface area among groups 
 
4.3.7 Summary of ImageJ stain surface area measurements 
 
The comparison of the markers among the groups showed significant differences 
for vWF synovium and vimentin only. ImageJ assessment of vascularity is not 
accurate, as explained in Section 4.3.1. Vimentin showed a significant difference 
between groups, being highest in group 1 and 2. Although not significant, the 
difference of the other markers showed a trend among the groups. They were higher 
in the obese young patients followed by young lean and old lean patients. These 
findings suggest an increased inflammatory response in the young obese patients. 
The total vascular markers (i.e. vWF and CD34) did not show any statistically 
significant difference.  
 
4.4 Comparison of other microvascular measurements 
Other important measurements were obtained and are listed in Table 4.9. 
 
4.4.1 Vascular density in the synovial intima 
 
The data showed no significant difference across groups for vascular density in 
the synovial intima (p = 0.915). The boxplot chart is shown in Figure 4.15. 
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Table 4.14: Comparison of vascular measurements (VDS= vascular density in 
synovium, SMC= smooth muscle cell) 
Groups (N=17) P value 
  Young Obese (G1, n =6) 
(Age<60, BMI>30)  
Young Lean (G2, n = 5) 
(Age<60, BMI<30)  
Old Lean (G3, n = 6) 
(Age>70, BMI<30) 
 
 
 
Median (SD) 
 
Median (SD) 
 
Median (SD) 
 
 
VDS  52.00(26.58) 45.00(4.42) 41.00(9.52) Across all groups :  
p= 0.915a 
Vessels with 
SMC  
10.00(2.70) 7.00(2.06) 13.00(4.18) Across all groups :  
p= 0.013a 
 
G1 > G2 : p =0.537b 
G1 < G3 : p = 0.283 b 
G2 < G3 : p = 0.010b 
 
Vessels with 
no SMC 
42.00(24.14) 36.50(4.79) 30.00(8.55) Across all groups :  
p= 0.305a 
VD Fat 28.00(19.52) 29.00(3.46) 23.00(10.45) Across all groups :  
p= 0.127a 
 
Vessel 
distance 
49.78(14.54) 50.17(4.54) 36.66(4.16) Across all groups :  
p= 0.023a 
G1 = G2 : p =1.000b 
G1 > G3 : p = 0.038 b 
G2 > G3 : p = 0.089b 
Vessel wall 
thickness 
16.05(5.86) 15.88(4.20) 11.85(3.47) Across all groups :  
p= 0.195a 
Mean fat cell 
diameter 
84.25(11.19) 64.41(6.74) 50.46(8.09) Across all groups :  
p= 0.002a 
G1 > G2 : p =0.221b 
G1 > G3 : p = 0.001 b 
G2 > G3 : p = 0.525b 
Note. a = Kruskall–Wallis test.  b = Dunn–Bonferroni post hoc test. 
 
Although the median suggests a decreasing trend from group 1 to group 3, it is 
difficult to draw a meaningful conclusion because of the outliers in groups 1 and 3. 
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Figure 4.15: Vascular density in the synovial intimal layer per group 
 
4.4.1.1 Intima vessels with smooth muscle cells layer 
 
The intimal vascular density was further evaluated for the presence of smooth 
muscle cells in the vascular wall. The data is shown in Table 4.9. It is interesting to 
see that the presence of SMC is significantly different across the groups (p = 0.013). 
This difference was noted between groups 1 and 3 according to the Dunn–
Bonferroni post hoc test readjustments. It showed that old lean people have 
increased numbers of vessels with smooth muscle cells, as shown in Figure 4.16.  
 
4.4.1.2 Intima vessels with no smooth muscle cells layer  
 
The number of intimal vessels that lack the SMC layer were also counted to 
relate it to the overall density. There was no significant difference across groups. 
However, this is an important finding. The boxplot in Figure 4.17 shows a trend of 
increased number of vessels lacking an SMC layer in the obese group, followed by 
the lean young and then the lean old group. 
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Figure 4.16: Intimal vessels with smooth muscle cells. 
 
 
  
Figure 4.17: Intimal vessels lacking smooth muscle cells. 
 
4.4.2 Vascular density in the fat section 
 
There was no significant difference across groups for the vascular density in the 
fat sections (p = 0.127). The statistical details are shown in Table 4.9. Figure 4.18 
gives a visual representation of the distribution. There was a trend of increased 
vascular density in the fatty sections of the obese people compared to in the other 
groups.  
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Figure 4.18: Vascular density in the fat area. 
4.4.3 Mean vessel distance from the surface of intimal synovium 
 
The mean distance of the vessels from the synovial surface is outlined in Table 
4.9. A significant difference across groups is demonstrated (p = 0.023). This 
significance is between groups 1 and 3, where group 1 shows an increased distance. 
Group 2 also has showed an increased distance when compared to group 3 but the 
Dunn–Bonferroni post hoc test readjustments gave a p value of (p = 0.089). The 
boxplot is shown in Figure 4.19. 
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Figure 4.19: Mean distance of the intimal synovial vessels from the synovial surface. 
 
4.4.4 Vessel wall thickness 
 
The largest vessels in each section were measured and the mean calculated to 
see if the wall thickness differed among the groups. Across group comparison did not 
show any significant difference. However, there is a trend of increasing vessel wall 
thickness in the obese young patients followed by the lean young and lean old 
people, as shown in Figure 4.20. 
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Figure 4.20: Vessel wall thickness. 
 
4.4.5 Summary of microvascular measurements 
 
The vascular measurements did not show any significant difference among the 
groups, except for the vessels with a smooth muscle layer in the synovial intima. 
Vessels in the synovial intima with a smooth muscle layer are significantly more 
abundant in the old age group (group 3), whereas the number of vessels that lack a 
smooth muscle layer were higher in the young obese group (group 1). Another trend 
of increased vascular density was observed in the fat sections. The young groups 
(groups 1 and 2) showed an increase in the distance of the nearest vessels to the 
synovial surface as well as the wall thickness. These results show that there are 
changes in the microcirculation in the synovium of these different groups. The 
increased vessel wall thickness (hyperplasia) is an important difference along with 
the vascular distance from the synovial surface. 
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4.5 Comparison of fat cell diameter in relation to other markers 
 
4.5.1 Mean fat cell diameter 
 
The data on the fat dimensions revealed a significant difference across groups (p 
= 0.002, Table 4.9). This difference is observed between groups 1 and 3 (G1 > G3: p = 
0.001). The box plot (Figure 4.21) shows some obvious differences between the 
groups, but this was not detected statistically. To assess how fat affects other 
markers, the results were divided into groups based on fat cell diameter (smaller and 
larger) and the Mann–Whitney U test applied across all the markers, irrelevant of 
groups. This comparison is shown in the following sections. 
 
 
Figure 4.21: Mean fat cell diameter. 
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Figure 4.22: The two fat categories (1= small, 2= large). 
 
4.5.2 Mean fat cell diameter comparison with other markers 
 
The patients were divided into small and large diameter fat cell groups after 
taking the average size of all the measurements and separating the groups into small 
size for those below the average and big size for those above the average. There was 
an equal distribution with eight patients in each group (one sample was not included 
as it did not contain fatty tissue; the results are shown in a box plot in Figure 4.22. 
There was only one patient who lied very close to the separation line. This 
assessment was done to see if the actual local fat burden as indicated by the fat cell 
diameter will affect the markers distribution regardless of the patient’s age and BMI.  
 
Table 4.10 shows the variables that exhibited a significant difference between 
the small and big fat cell diameter group. 
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Table 4.15: The variables with significant difference between the small and large 
fat cell groups (S= synovium, VDF= vascular density in fat, SMC= smooth muscle 
cell) 
 
 vWF S CD68 
Total 
CD3 
Total 
CD20 
Total 
Vimentin 
Total 
Vessel 
distance  
VDF VD 
with 
SMC 
P value 0.004 0.035 0.016 0.046 0.014 0.046 0.028 0.021 
 
The difference with the synovial vWF was significant. The vWF was higher in the 
small size fat cells. The reason for this difference was explained in Section 4.3.1. A 
similar difference was observed with the vessels with a smooth muscle layer where 
an increase in size of the fat cells correlated with a decrease in the number of vessels 
with a smooth muscle layer. The boxplots in Figures 4.23 and 4.24 show this 
comparison. On the other hand, CD68 total (macrophage marker), CD3 total (T-cell 
marker), CD20 total (B-cell marker), vimentin synovium (cytoskeleton protein), 
vimentin fat, vimentin total, intimal vessel distance from the synovial surface and 
vascular density in the fat section showed an increase with increased size of the fat 
cells.  
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Figure 4.23: The boxplots shows comparison of fat cell size (1= small fat cell group, 2= large 
fat cell group) with synovial vWF (A), CD68 total (B), CD3 total (C) and CD20 total (D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 4.24: The boxplots shows comparison of fat cell size (1= small fat cell group, 2= large 
fat cell group) with vimentin synovium (A), vimentin fat (B), vimentin total (C), intimal vessel 
distance from synovial surface (D), vascular density in fat sections (E), number of vessels with 
smooth muscle layer (F).  
 
B 
D 
F 
A 
C 
E 
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4.5.3 Summary of fat cell comparison 
 
Fat cell size affected several markers as outlined above. The increase in fat cell 
size correlated with an increase in the inflammatory markers of macrophages, T 
cells, B cells and fibroblasts. Moreover, the number of vessels in fatty sections 
increased with increased fat cell size. These results suggest that an increase in the fat 
cell size has a major role in the inflammatory response.  
 
4.6 Correlations 
 
Tables 4.11, 4.12, 4.13, 4.14 and 4.15 depict the data and details of correlations. 
All the markers have been correlated with each other and with other parameters. 
The correlations are summarised as follows: 
 
4.6.1 Age and inflammatory markers in the synovial sections 
 
Age had a very significant negative correlation with BMI, CD3 and vimentin in the 
synovium sections. The relationship between age and BMI has been explained earlier 
and it is important to see how the synovium differs among the groups with different 
BMIs. In the synovial sections, CD3 and vimentin showed a significant negative 
correlation with age. Although not significant, there was a negative correlation with 
other markers, including CD68 and CD20. These findings suggest that the 
inflammatory response is lower in the synovium of the old age group. For details of 
the results, refer to Table 4.11. 
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Table 4.16: Table of correlation of Age and BMI with all the markers measured in 
the synovial sections. 
 
  Age BMI vWF S CD34 
S 
CD68 S CD3 S CD20 S Vim S 
Age Correlation 
Coefficient 
1.000 -0.754** 0.564* 0.275 -0.338 -0.646* -0.209 -0.792** 
 P value . 0.000** 0.036* 0.322 0.219 0.017* 0.473 0.000 
BMI Correlation 
Coefficient 
-0.754** 1.000 -0.459 -0.154 -0.154 0.484 0.389 0.654** 
 P value 0.000** . 0.098 0.585 0.585 0.094 0.169 0.008 
vWF S Correlation 
Coefficient 
0.564* -0.459 1.000 0.411 -0.481 -0.324 -0.343 -0.720** 
 P value 0.036* 0.098 . 0.144 0.081 0.280 0.276 0.006** 
CD34 S Correlation 
Coefficient 
0.275 -0.154 0.411 1.000 -0.479 -0.170 -0.220 -0.226 
 P value 0.322 0.585 0.144 . 0.071 0.578 0.471 0.436 
CD68 S Correlation 
Coefficient 
-0.338 -0.154 -0.481 -0.479 1.000 0.577* 0.121 0.640* 
 P value 0.219 0.585 0.081 0.071 . 0.039* 0.694 0.014* 
CD3 S Correlation 
Coefficient 
-0.646* 0.484 -0.324 -0.170 0.577* 1.000 0.627* 0.615* 
 P value 0.017* 0.094 0.280 0.578 0.039* . 0.039* 0.025* 
CD20 S Correlation 
Coefficient 
-0.209 0.389 -0.343 -0.220 0.121 0.627* 1.0
00 
0.238 
 P value 0.473 0.169 0.276 0.471 0.694 0.039* . 0.457 
Vim S Correlation 
Coefficient 
-0.792** 0.654** -0.720** -0.226 0.640* 0.615* 0.238 1.000 
 P value 0.000** 0.008** 0.006** 0.436 0.014* 0.025* 0.457 . 
*Significant correlation at 0.05 ** Significant correlation at 0.01 
 
4.6.2 Age and inflammatory markers in the total sections 
 
The inflammatory markers (i.e. CD3, CD20, CD68 and vimentin) combined in the 
synovium and the fat sections showed similar correlations when compared to the 
synovial sections. This kind of correlation suggests that the older patients are not 
showing a significant inflammatory response despite having the same grade of OA as 
compared to the young group of patients, as shown in Table 4.14. 
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4.6.3 Age and vascular measurements 
 
A significant positive correlation of age was observed with the synovial vWF 
marker. There was also a positive correlation between age and CD34 but not 
significant. Although age had a positive correlation with vWF and CD34, it was 
correlated negatively with the other vascular measurements. Vascular density in the 
synovium (VDS) and fat (VDF) sections and the vascular density of the vessels that 
lack a smooth muscle layer (vessels with no SMC) correlated negatively with age. In 
addition, a negative correlation was observed with the vascular wall thickness, vessel 
distance from synovial surface and fat cell diameter. On the other hand, there was a 
positive correlation between age and the vessels that had a smooth muscle layer. 
The accuracy of the vWF and CD34 results obtained by ImageJ has been explained in 
Section 4.3.1 and might explain why there was discrepancy between the vWF and 
CD34 measured by the ImageJ software and the other vascular measurements. Table 
4.12 shows the statistical correlations and data in detail. 
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Table 4.17: Table of correlation of age, BMI and all the markers in the synovial 
sections with all the vascular measurements 
  MVDS MVDF MVD 
(SMC) 
MVD 
(No SMC) 
Wall 
thickness 
Vessel 
distance 
Fat cell 
diameter 
Age Correlation 
Coefficient 
-0.042 -0.479 0.417 -0.279 -0.437 -0.644* -0.738** 
 P value 0.886 0.083 0.138 0.334 0.119 0.013* 0.001** 
BMI Correlation 
Coefficient 
0.048 0.252 -0.150 0.183 0.319 0.407 0.724** 
 P value 0.869 0.385 0.608 0.532 0.267 0.149 0.002** 
vWF S Correlation 
Coefficient 
-0.196 -0.397 0.537* -0.381 -0.253 -0.456 -0.742** 
 P value 0.502 0.159 0.048* 0.179 0.405 0.117 0.004** 
CD34 S Correlation 
Coefficient 
0.172 0.252 0.175 0.084 0.156 -0.095 -0.073 
 P value 0.557 0.385 0.551 0.776 0.594 0.47 0.805 
CD68 S Correlation 
Coefficient 
-0.172 0.325 -0.754** 0.051 0.415 0.262 0.068 
 P value 0.557 0.258 0.002** 0.864 0.140 0.336 0.817 
CD3 S Correlation 
Coefficient 
0.170 0.326 -0.464 0.380 0.676* 0.687** 0.462 
 P value 0.578 0.277 0.110 0.201 0.011* 0.010** 0.131 
CD20 S Correlation 
Coefficient 
0.343 -0.011 0.224 0.301 0.448 0.168 0.154 
 P value 0.275 0.974 0.484 0.341 0.145 0.602 0.616 
Vim S Correlation 
Coefficient 
0.253 0.497 -0.724** 0.514 0.508 0.666** 0.727** 
 P value 0.405 0.084 0.005** 0.072 0.064 0.009** 0.003** 
*Significant correlation at 0.05 ** Significant correlation at 0.01 
 
4.6.4 BMI and inflammatory markers in the synovial sections 
 
The relationship between BMI and the inflammatory markers was the opposite 
of the age relationship. In the synovial sections, CD3, CD20 and vimentin were 
positively correlated with increased BMI. Vimentin had a very significant correlation. 
Interestingly, CD68 was correlated negatively with the BMI. However, when looking 
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at the total CD68, the relationship followed the other markers. Refer to Table 4.11 
for further details. 
 
4.6.5 BMI and inflammatory markers in the total sections 
 
The inflammatory markers in the total sections showed similar correlations when 
compared to the synovial sections. This is an indication that increasing weight is 
correlated with increasing inflammatory response. Details are shown in Table 4.14. 
 
Table 4.18: Table of correlation of the vascular measurements with each other  
  MVDS MVDF MVD 
(SMC) 
MVD 
(No SMC) 
Wall 
thickness 
Vessel 
distance 
Fat cell 
diameter 
MVDS Correlation 
Coefficient 
 1.000 0.014 0.200 0.925** 0.110 0.385 0.228 
 P value  0.961 0.493 0.000** 0.721 0.194 0.453 
MVDF Correlation 
Coefficient 
0.014 1.000 -0.529 0.158 0.776** 0.395 0.502 
 P value 0.961  0.052 0.590 0.002** 0.182 0.080 
MVD 
(SMC) 
Correlation 
Coefficient 
0.200 -0.529 1.000 -0.146 -0.453 -0.464 -0.373 
 P value 0.493 0.052  0.618 0.120 0.110 0.209 
MVD 
(No SMC) 
Correlation 
Coefficient 
0.925 0.158 -0.146 1.000 0.217 0.597* 0.465 
 P value 0.000 0.590 0.618  0.476 0.031* 0.109 
Wall 
thickness 
Correlation 
Coefficient 
0.110 0.776** -0.453 0.217 1.000 0.547* 0.489 
 P value 0.721 0.002** 0.120 0.476  0.043* 0.09 
Vessel 
distance 
Correlation 
Coefficient 
0.385 0.395 -0.464 0.597* 0.547* 1.000 0.648* 
 P value 0.194 0.182 0.110 0.031* 0.043*  0.017* 
Fat cell 
diameter 
Correlation 
Coefficient 
0.228 0.502 -0.373 0.465 0.489 0.648* 1.000 
 P value 0.453 0.080 0.209 0.109 0.09 0.017*  
*Significant correlation at 0.05 ** Significant correlation at 0.01 
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4.6.6 Other correlations 
4.6.6.1 CD68 vs. age  
 
Although there was a negative correlation between CD68 and age, this 
correlation was weak with a correlation coefficient of -0.314 (p = 0.254). See Tables 
4.14 and 4.15 for details.  
 
4.6.6.2 CD68 vs. BMI 
 
BMI showed a positive correlation with CD68. This correlation was weak. 
However, it showed a significant positive correlation with fat cell diameter. See 
Tables 4.14 and 4.15 for details. 
4.6.6.3 CD68 vs. vascular measurements  
 
There was a very strong significant correlation between CD68 and the vascular 
density in the fat sections. There was also a weak positive correlation observed 
between MVDS and CD68. Vascular wall thickness and fat cell diameter were 
correlated significantly. This relationship is expected because, as the vascularity 
increases, the number of inflammatory cells like macrophages increase. On 
assessment of the MVD with SMC, it was found to have a significant negative 
correlation. So, macrophages increase in number with increased vascularity. See 
Tables 4.14 and 4.15 for details.  
4.6.6.4 Vimentin vs. age 
 
Vimentin exhibited a similar pattern of correlation to CD68. However, the 
strength of the correlation was different. There was a very strong significant 
negative correlation between vimentin and age. See Tables 4.14 and 4.15 for details. 
 
4.6.6.5 Vimentin vs. BMI 
 
Although not significant, there was a positive correlation between vimentin and 
BMI. The fat cell diameter showed a significant positive correlation with vimentin. 
See Tables 4.14 and 4.15 for details. 
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4.6.6.6 Vimentin vs. vascular measurements  
 
The vascular measurements showed a positive correlation with vimentin, except 
for MVD with SMC, which showed the complete opposite. These findings are in 
agreement with the CD68 findings in relation to the vascular parameters. See Tables 
4.14 and 4.15 for details. 
Table 4.19: Correlation of age and BMI with all the markers in the whole tissue 
sections 
  Age BMI vWF 
Total  
CD34 
Total  
CD68 
Total 
CD3 
Total 
CD20 
Total 
Vim 
Total 
Age Correlation 
Coefficient 
1.000 -0.754** 0.071 0.066 -0.314 -0.554* -0.202 -0.588* 
 P value  0.000** 0.810 0.814 0.254 0.049* 0.448 0.021* 
BMI Correlation 
Coefficient 
-0.754** 1.000 -0.015 -0.029 0.232 0.357 0.284 0.461 
 P value 0.000**  0.958 0.919 0.405 0.231 0.326 0.084 
vWF 
Total 
Correlation 
Coefficient 
0.071 -0.015 1.000 0.908** 0.204 0.104 0.042 0.242 
 P value 0.810 0.958  0.000** 0.483 0.734 0.897 0.426 
CD34 
Total 
Correlation 
Coefficient 
0.066 -0.029 0.908** 1.000 0.296 0.071 0.154 0.257 
 P value 0.814 0.919 0.000**  0.283 0.817 0.616 0.375 
CD68 
Total 
Correlation 
Coefficient 
-0.314 0.232 0.204 0.296 1.000 0.857** 0.495 0.912** 
 P value 0.254 0.405 0.483 0.283  0.000** 0.086 0.000** 
CD3 
Total 
Correlation 
Coefficient 
-0.554* 0.357 0.104 0.071 0.857** 1.000 0.818** 0.835** 
 P value 0.049* 0.231 0.734 0.817 0.000**  0.002** 0.000** 
CD20 
Total 
Correlation 
Coefficient 
-0.202 0.284 0.042 0.154 0.495 0.818** 1.000 0.427 
 P value 0.448 0.326 0.897 0.616 0.086 0.002**  0.167 
Vim 
Total 
Correlation 
Coefficient 
-0.588* 0.461 0.242 0.257 0.912** 0.835** 0.427 1.000 
 P value 0.021* 0.084 0.426 0.375 0.000** 0.000** 0.167 . 
*Significant correlation at 0.05 ** Significant correlation at 0.01 
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4.6.6.7 CD3 and CD20 vs. age 
 
CD3 showed a significant negative correlation with age. On the other hand, CD20 
showed a weak negative correlation with age. See Tables 4.14 and 4.15 or details. 
4.6.6.8 CD3 and CD20 vs. BMI 
 
In contrast to age, they showed a positive correlation with BMI. However, it was 
not a significant correlation. See Tables 4.14 and 4.15 for details. 
4.6.6.9 CD3 and CD20 vs. vascular measurements 
 
Both markers exhibited a similar type of relationship with vascular 
measurements as that for CD68 and vimentin, except for MVDS where the 
correlation was negative for CD3. See Tables 4.14 and 4.15 for details. 
 
Table 4.20: Correlation of all the markers in the whole tissue sections with the 
vascular measurements 
  MVDS MVDF MVD 
(SMC) 
MVD 
(No SMC) 
Wall 
thickness 
Vessel 
distance 
Fat cell 
diameter 
vWF Total Correlation 
Coefficient 
-0.189 0.227 -0.020 -0.200 0.505 -0.176 -0.154 
 P value 0.517 0.434 0.946 0.493 0.078 0.566 0.616 
CD34 Total Correlation 
Coefficient 
-0.031 0.375 -0.110 -0.002 0.538* 0.015 0.011 
 P value 0.917 0.186 0.707 0.994 0.047* 0.958 0.970 
CD68 Total Correlation 
Coefficient 
0.002 0.702** -0.698** 0.218 0.714** 0.389 0.569* 
 P value 0.994 0.005** 0.005** 0.454 0.004** 0.169 0.034* 
CD3 Total Correlation 
Coefficient 
-0.016 0.613* -0.597* 0.135 0.615* 0.346 0.601* 
 P value 0.957 0.026* 0.031* 0.661 0.025* 0.247 0.039* 
CD20 Total Correlation 
Coefficient 
0.021 0.485 -0.049 0.098 0.545 0.056 0.489 
 P value 0.948 0.110 0.880 0.762 0.067 0.863 0.09 
Vim Total Correlation 
Coefficient 
0.027 0.688** -0.801** 0.261 0.741** 0.547* 0.653* 
 P value 0.929 0.009** 0.001** 0.338 0.002** 0.043* 0.011* 
*Significant correlation at 0.05 ** Significant correlation at 0.01 
104 | P a g e  
 
 
4.6.7 Correlations in linear regression plots 
 
The regression plots shown in Figures 4.25 to 4.31 explain the relationships of 
the different variables in a visual easy-to-follow way. For example, Figure 4.25 shows 
the relationship of age and BMI with vWF in synovium, fat and total sections. The 
positive correlation with age and the negative with BMI is shown very clearly. A 
similar pattern can be observed in Figure 4.26 for CD34 in the fat and total sections. 
In Figure, 4.26 mean fat cell diameter showed a significant negative correlation with 
age and a positive correlation with BMI.  
 
The total measurements of CD3, CD20 and vimentin showed obvious negative 
correlations with age and positive correlations with BMI, as shown in Figure 4.27. 
The correlations between vascular measurements and age and BMI are shown in 
Figures 4.28 and 4.29. There was a positive correlation between age and the vessels 
with a smooth muscle layer whereas the opposite was observed with BMI. All the 
other vascular measurements correlated negatively with age and positively with 
BMI. 
 
The CD68 correlations are shown in Figure 4.30. There is a negative correlation 
between age and CD68 in the synovium, fat and total sections. On the other hand, 
BMI correlated positively with CD68 measurements. 
 
Figure 4.31 shows the correlations of CD3, CD20 and Vimentin in fat sections 
with age and BMI. They all exhibited a positive correlation with BMI and a negative 
correlation with age. Vimentin showed very significant correlations with age and BMI 
with a narrow confidence interval.  
 
The overall correlations suggested an increased inflammatory response in the 
young age groups (i.e. groups 1 and 2). The increase in weight (i.e. group 1) also 
suggested an increase in the inflammatory response.  
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Figure 4.25: Regression plots, showing correlation of Age with vWF in the synovium (A), 
Fat(C) and vWF total (E). The correlation of BMI with vWF in the synovium (B), Fat (D) and 
vWF total (F). vWF showed Positive Correlation with the Age and negative correlation with 
BMI 
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Figure 4.26: Regression plots, showing correlation of Age with CD34 in fat (A), CD34 in total 
sections (C) and mean fat cells diameter (E). The correlation of BMI with CD34 in fat (A), 
CD34 in total sections (C) and mean fat cells diameter (E). CD34 showed very weak positive 
correlation with the age and negative correlation with BMI. Mean fat cells diameter showed 
significant negative correlation with age and significant positive correlation with BMI. 
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Figure 4.27: Regression plots, showing correlation of Age with CD3 total (A), CD20 total (C) 
and Vimentin total (E). The correlation of BMI with CD3 total (B), CD20 total (D) and 
Vimentin total (F). Age showed negative correlation with the above markers whereas BMI 
correlated positively. 
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Figure 4.28: Regression plots, showing correlation of Age with vascular density in the 
synovium (A), the vascular density in fat (C) and vessels with smooth muscle layer in the 
synovium (E). The correlation of BMI with vascular density in the synovium (B), the vascular 
density in fat (D) and vessels with smooth muscle layer in the synovium (F). Age showed 
negative correlation with the vascular density in synovium and fat sections whereas BMI 
correlated positively. Vessels with smooth muscle layer correlated positively with age and 
negatively with BMI. 
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E F 
109 | P a g e  
 
  
  
  
 
Figure 4.29: Regression plots, showing correlation of Age with vessels lacking smooth muscle 
layer (A), mean vessel wall thickness (C) and mean intimal vessels distance from synovial 
surface (E). The correlation of BMI with vessels lacking smooth muscle layer (B), mean vessel 
wall thickness (D) and mean intimal vessels distance from synovial surface. Age showed 
negative correlation with the above measurements whereas BMI correlated positively.  
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Figure 4.30: Regression plots, showing correlation of age with CD68 in the synovial sections 
(A), CD68 in the fat sections(C) and CD68 in the total sections (E). The correlation of BMI with 
CD68 in the synovial sections (B), CD68 in the fat sections (D) and CD68 in the total sections 
(F). Age showed negative correlation with the above measurements whereas BMI correlated 
positively. 
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Figure 4.31: Regression plots, showing correlation of age with vimentin in fat sections (A), 
CD20 in the fat sections (C) and CD3 in the fat sections (E). The correlation of BMI with 
vimentin in fat sections (A), CD20 in the fat sections (C) and CD3 in the fat sections (E). Age 
showed negative correlation with the above measurements whereas BMI correlated 
positively. 
 
4.6.8 Summary of correlations 
 
A negative correlation was observed between age and CD68, CD3, CD20 and 
vimentin. In other words, the inflammatory response was lower in the older age 
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group. In contrast, there was a positive relationship with BMI. This indicates that an 
increase in BMI is associated with an increase in the inflammatory response. The 
vascular measurements showed a negative correlation with age and a positive one 
with BMI, except for the number of vessels with a smooth muscle layer. 
 
 
4.7 Semi-quantitative assessments 
 
The slides were also assessed using semi-quantitative scoring where the cells 
expression were assessed. Table 4.16 shows the results of the scoring. 
 
4.7.1 vWF 
 
vWF showed strong expression in the majority of the patients in terms of the 
stain intensity and the number of vessels. This does not agree with the ImageJ 
findings. However, this measures the intensity of expression rather than the actual 
surface area. 
4.7.2 CD34 
 
CD34 showed a very strong expression in all the patients, which explains the 
entire vascular expression in the whole sections. This follows the same pattern as 
vWF. 
4.7.3 CD68 
 
CD68 showed stronger expression in the young age group patients (groups 1 and 
group 2), whereas weaker expression was observed in the old age group people. This 
is in agreement with the ImageJ findings.  
4.7.4 CD3 
 
CD3 followed the same pattern as CD68 with more expression in groups 1 and 2 
as compared to group 3. This also agreed with the ImageJ findings. 
4.7.5 CD20 
 
113 | P a g e  
 
CD20 did not follow any specific trend. However, more expression was observed 
in groups 1 and 2. 
4.7.6 Vimentin 
 
Vimentin showed a very significant difference in terms of expression. It was 
strongly expressed in groups 1 and 2. On the other hand, the expression was weak in 
group 3. These findings match up with the ImageJ findings. 
 
Table 4.21: Semi quantitative scores (G1: group 1, G2: group 2, G3: group 3; the 
number represent the number of patients in each category): 
  0 1+ 2+ 
vWF   G1 0 1 5 
  G2 0 1 4 
  G3 0 1 5 
CD34  G1 0 0 6 
  G2 0 0 5 
  G3 0 0 6 
CD68  G1 0 1 5 
  G2 0 1 4 
  G3 0 3 3 
CD3  G1 0 3 3 
  G2 1 1 3 
  G3 1 3 2 
CD20   G1 4 1 1 
  G2 2 1 2 
  G3 3 2 1 
Vimentin  G1 0 0 6 
  G2 0 0 5 
  G3 0 6 0 
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4.8 Chronic synovitis scoring 
 
The slides were assessed for evidence of synovitis. They were scored as shown in 
Table 4.17. There were no obvious differences among the groups. However, the 
majority of the patients in all three groups showed evidence of low-grade synovitis. 
The pie chart in Figure 4.32 shows the distribution of chronic synovitis among all the 
groups. 
 
 
 
Table 4.22: Chronic synovitis scoring outcome. 
 No synovitis Low-grade synovitis High-grade synovitis 
Group 1 3 2 1 
Group 2 1 4 0 
Group 3 2 3 1 
 
 
 
 
 
Figure 4.32: Chronic synovitis distribution. Low grade synovitis is shown in over half of the 
patients.  
 
 
35%
53%
12%
Chronic synovitis distribution 
No synovitis Low grade synovitis High grade synovitis
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Figure 4. 33: Examples of IHC staining of all the markers across groups 
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Figure 4. 34: Examples of vascular wall thickness (the black single head arrows point to the 
vascular smooth muscle layers, the black double headed arrows point to the vessel wall 
thickness, the blue double headed arrows point to the synovial intima) 
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4.9 Other abnormal findings 
 
Vessels with intimal hyperplasia were observed in some sections, mainly in the 
young and more so in the young obese people (Figures 4.34 and 4.35). 
 
 
 
Figure 4. 35: Synovial sections from obese people showing significant vascular hyperplasia 
very close to the intimal surface (blue arrows pointing to the smooth muscle layer, black 
double headed arrows point to the vascular wall thickness, single head small black arrows 
point to normal capillaries). 
 
The presences of the smooth muscle layers suggest that they are either arteries 
or arterioles. However, they are very close to the intimal synovial layer, so they are 
unlikely to be a bigger vessel like an artery. It is most likely that they represented 
A 
B 
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arterioles. It is expected to see capillaries at this level of the synovial sections to 
allow for the exchange of molecules. It is difficult to explain why these vessels have a 
smooth muscle layer very close to the intimal surface. One explanation is that it 
might suggest a local manifestation of a systemic problem like atherosclerosis, which 
is linked to obesity. However, this was also observed in the young lean people, the 
majority of whom are smokers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
119 | P a g e  
 
5. DISCUSSION 
 
5.1 Patient selection 
 
 
OA is a multifactorial condition. Of the multiple risk factors, age and genetics 
have been established as independent risk factors (Goldring and Goldring, 2006). It is 
still believed that OA is a wear and tear problem. The understanding of OA has 
evolved with multiple theories existing to solve its mystery. There is growing 
evidence of a chronic inflammatory response involved in the process of OA 
development, especially metabolic syndrome (Brooks, 2003, Benito et al., 2005, 
Smith et al., 1997, Spector et al., 1997, Martinek, 2003, Goldring and Otero, 2011, 
Clockaerts et al., 2010). Despite the huge body of research on OA, there is nothing 
mentioned about the synovial changes in the young obese people in terms of 
inflammation and microcirculation. It is still a mysterious area. This project has 
focused on these two aspects of the synovium to gain in-depth knowledge of the 
changes encountered in this subgroup of patients. Moreover, young and old lean 
patients were studied in the same way to find out if there is a pattern of changes in 
their synovium. One of the questions that required an answer was why the old 
people manage to have their knee replacements very late in life compared to the 
young obese patients, who gets their knee replacements fairly early. What is it in 
their synovium that predisposes them to the early OA? Is it inflammation? Is it 
mechanical problems? Is it a local or systemic problem? What happens to their 
synovial microcirculation? All these questions require an answer. 
 
To be able to answer these questions, careful patient selection was necessary. 
This type of research is difficult to carry out because of the nature of the condition 
and the multiple risk factors involved. The selection criteria were strict to avoid the 
influence of any risk factors that could affect the results. The groups of patients in 
this study were matched in many aspects. They all share the same degree of 
advanced OA as indicated by the radiological KL score and the functional WOMAC 
score. They all share similar levels of health status with almost similar ASA grades 
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and the number of comorbidities was evenly distributed among groups. Gender was 
also matched for male and female representation. However, smoking was more 
prevalent in the young lean group, which was not found to be significantly different 
when comparing smoking with all the markers. Moreover, to be able to illicit a 
difference as a result of smoking, a larger number of patients would be required. The 
selected group of patients differed in their age and BMI but were almost matched 
for other clinical risk factors. 
 
5.2 The synovial microcirculation 
 
Levick studied the microcirculation of the synovium in rabbits and humans and 
his work helped in the assessment of synovial microcirculation in this project (Levick, 
1995). Others have also looked into the synovium and examined vascularity using 
vWF (Pessler et al., 2008a, Pessler et al., 2008b, Mucke et al., 2016). In this project, a 
combination of methods was used to assess the vascular changes in relation to age 
and BMI. This is the first time that synovial vascularity has been assessed extensively. 
Several measurements were taken from the histological slides, including: digital 
measurement of stain surface area of vWF and CD34, manual count of intimal 
vascular density in the hot area, which is further divided to number of capillaries (no 
smooth muscle layer) and arterioles (smooth muscle layer present), the vascular wall 
thickness (hyperplasia) and the distance of the vessels to the surface of the 
synovium. The idea was to see if fat was associated with the vascular changes and 
how old people’s synovia differ from those of young people.  
 
The data of the overall vascularity using CD34 and the activated blood vessels 
using vWF showed an overall increasing trend of both markers in the old lean group. 
This finding might not be an accurate representation of the actual situation, as 
discussed in Section 3.3.1. Although the trend is obvious, there was no significant 
difference between groups in the overall vascularity. On the other hand, the manual 
counts of activated capillaries in the synovial intima showed a trend of increasing 
density in the young obese group. There were no previous papers to compare the 
microcirculation against. 
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Another parameter of importance is the vessel distance from the synovial 
surface, which is important to achieve easy transport of nutrients to the joint. A 
trend of increasing vessel distance from the synovial surface was noted in the young 
age groups. In fact, the vessel distance measurement of the old group people agreed 
with Levick’s findings of normal vessel distance for the human synovium. Levick 
reported 35 µm for a normal synovium intimal vessel distance from the joint, which 
is very close to what was observed in this research (mean (SD) 36.66 µm (4.16)). This 
could be a reason why the old people maintain their articular surface for longer 
when compared to the young people with OA. 
 
Vessel hyperplasia was also assessed as a local manifestation of the systemic 
problem of increased fat. There was no significant difference among the groups. 
However, a trend of increasing wall thickness was observed in the young obese 
people. More importantly, these changes were observed very close to the intimal 
surface of the synovium; an example of this finding is shown in Figure 4.35. One 
could argue that these vessels are actually larger vessels from the vascular tree. 
Although this might be true for sections deep in the synovium, it would not be 
accepted for intimal vessel to be that thick and be able to function. When combining 
the vessel wall thickness and the vessel distance from the synovial surface, obese 
people’s joints will suffer from defective nutrient supply and hence early OA. 
Although this argument might be clear for the young obese people, it cannot explain 
why the young lean group suffers the same fate. It is possible that the smoking effect 
in this group caused these changes; however, this cannot be concluded as the 
condition is multifactorial and we do not know much about the detailed background 
of this groups in terms of activities and previous injuries that could have led to the 
advanced OA changes. Furthermore, the changes that are observed are more 
pronounced in the obese people compared to the other patients.  
 
The groups were re-distributed based on the fat cell size and the measurements 
were reassessed to see if fat cell diameter (local fat burden) affects the vascularity. 
The data supported the previous findings. Increased fat cell size showed a significant 
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increase in the density of the vessels in the fat sections as well as the vessel distance 
to the synovial surface.  
 
The semi-quantitative assessment did not show any differences across the 
groups for the vascular expressions. It could be argued that there is no significant 
difference in the overall vascularity because we are looking at a similar advanced 
stage of OA.  
 
In summary, fat is definitely associated with changes to the synovial 
microvascularity, as observed in our data. It also may suggest a systemic problem, 
although this is difficult to prove until we examine other tissues.  
 
5.3 Synovial inflammatory response 
 
The inflammation in OA has been studied in the past and there are several 
articles that have addressed this before. However, it has not been looked at in 
relation to the fat cell diameter. The inflammatory markers used in this research 
were CD68 (macrophages), CD3 (T cells), CD20 (B cells) and vimentin (fibroblasts).  
 
When looking into the comparison across groups, there were no significant 
differences noted, except for vimentin, which was significantly low in the old age 
group. Although there were no significant differences across groups, CD68, CD3 and 
CD20 showed an increasing trend toward the young groups with the highest levels in 
the young obese people.  
 
The significant difference of vimentin observed in the old age group could be 
attributed to various reasons. Vimentin is a cytoskeleton protein that helps to 
maintain the structure of the cell (Fuchs and Weber, 1994). It is highly expressed in 
fibroblasts but also has some expression in other cells, including T and B cells. 
Fibroblasts are very well known for their role in tissue repair (Cheng et al., 2016). 
This leads us to believe that the young people are experiencing ongoing tissue 
damage and repair, as expressed by the increased amount of vimentin expression in 
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the young age group. Another possibility is that the old age group do not cause 
tissue damage with their routine activity owing to their lower activity level. 
Furthermore, it could be that the tissue is not capable of producing more vimentin 
owing to age and cellular senescence. 
 
However, when redistributing the patients into those with large and small fat cell 
diameters, there was a significant difference between groups. The large fat cells 
attracted more inflammatory cells. Thus, when ignoring age and BMI, the increased 
size of the fat cells was linked to an increased inflammatory response. These findings 
support the inflammatory theory of metabolic OA. This research finding is an 
agreement with the published data on the effect of fat on the low-grade 
inflammatory response (Clockaerts et al., 2010, Goldring and Otero, 2011, Wang et 
al., 2011, Nair et al., 2012). Although there is very strong evidence that fat in obese 
people is an obvious cause of inflammation, the mechanical part of obesity cannot 
be ignored. Obese patients have greater sagittal-plane knee moments and greater 
knee-joint loads than normal-weight adults (Browning and Kram, 2007). Mechanical 
stress is important for the living of chondrocytes. However, injurious stress causes 
alteration of the articular cartilage extracellular matrix, leading to depletion of 
proteoglycan molecules and shedding of articular cartilage, which is considered to be 
inflammatory trigger on its own (Torzilli et al., 2010, Ding et al., 2010).  
 
In summary, obesity acts through different mechanisms to cause early OA in 
young people. Fat makes a major contribution to the inflammatory response, as 
shown in our data, and it is expressed as a systemic problem, as demonstrated by 
the vascular changes. 
 
5.4 The hypotheses 
The main hypothesis is that vascular and inflammatory components of synovial 
tissue, debrided at primary knee arthroplasty for osteoarthritis, will vary with age 
and BMI. The increased fat leads to neo-angiogenesis and hence inflammation, 
which causes the early OA. Therefore, the null hypothesis has been rejected. There is 
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evidence of vascular and inflammatory differences among the groups of different 
ages and BMI. 
The secondary questions were: 
1- The effect of fat in the synovial tissue and its relation to angiogenesis. The 
data support adiposity as a cause of increased inflammation but not the only 
cause. In addition, the vascularity increased with increased fat cell diameter. 
2-  The changes in microcirculation in the synovium were studied and showed 
an interesting finding of variable wall thickness and distance from the 
synovial surface. The young obese patients showed an increase in both 
variables when compared to the other groups. 
3- The relation of vascular changes and other inflammatory cells. The 
inflammatory cells were correlated positively with the vascular 
measurements, which could indicate that increased inflammation causes new 
vessel formation, which attracts more inflammatory cells. 
4- The most predominant inflammatory cell type in all groups was 
macrophages. Fibroblasts were also observed in the young age groups 
(groups 1 and 2). 
5- The synovitis scoring in all the groups was predominantly low grade. High-
grade synovitis was also observed in all the groups but few patients had it.  
 
5.5 Interesting finding 
 
The synovium has been evaluated before but nothing has been mentioned about 
the vascular changes. A lot of attention was given to the cellular and extracellular 
changes. It was interesting to see very hyperplastic vessels very close to the synovial 
intimal surface. Levick gave a detailed description of what the vessel structure 
should look like to be able to carry out its function as a conduit of molecule 
exchange (Levick, 1995). More vascular hyperplasia was observed in the obese 
specimens and to a lesser extent in the other groups. One could argue that the 
vascular hyperplasia seen in the synovium could be the case in the rest of the body 
and this further supports the idea of the systemic metabolic process involved in 
obese people with OA. This was examined carefully to avoid misinterpretation. The 
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vascular anatomy changes depending on the section it is taken from. For example, 
the vessel could be taken at the level where it is still an artery and supposed to have 
a thick wall. Bearing this in mind, it could be that the sections have been taken at 
such a level. However, these vessels were observed very close to the intimal surface, 
where the vessels should be changing from arterioles to capillaries. These vessels 
most likely represent hyperplastic arterioles, indicating a change of atherosclerosis, 
which is a very well-established sign of a systemic vascular problem that is linked to 
obesity (Rocha and Libby, 2009, Libby et al., 2010). This further supports the concept 
of a systemic problem of obesity and adiposity as a cause of early OA. The common 
link between all is inflammation. 
We are led to believe that obesity and adiposity contribute to vascular 
dysfunction, which leads to a decrease in tissue nutrition. The tissue is placed under 
constant hypoxic drive, which causes the inflammation and early development of 
OA.  
 
5.6 Study strength  
 
Although this project is expected to have many limitations, it has some strengths. 
Its strength lies in the fact that it is the first time the synovium has been analysed in 
depth, especially for obese patients. A holistic approach to the synovium was 
followed starting from the gross appearances down to the details of the vascularity 
and the cellular changes involved in synovitis. The examination of the synovium was 
from the prospect of inflammation as a serious cause of early OA. Moreover, careful 
patient selection was done, which possibly led to the low sample size. The strict 
inclusion and exclusion criteria were important to avoid non-specific results, 
especially in a condition like OA where there are many factors that could lead to the 
same end result. Despite the huge diversity of patients from the age and BMI point 
of view, they were matched for the majority of other relevant clinical parameters. 
Furthermore, blinding was done while examining and analysing the ImageJ data, 
which was important to avoid bias in the adjustment of the threshold of stain 
detection. 
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5.6 Challenges and limitations 
 
At the start of this project, it was anticipated that there would be many 
challenges owing to the nature of the condition. They include: 
- The selection of patients to be grouped in different categories and then 
comparing them would raise the concern of comparing completely 
different groups and the comparison would then not be justified. 
However, this was considered and the groups were matched for almost 
all the parameters, except for age and BMI, which are the focus of this 
project and we wanted to see how they affect the condition. 
- Although we tried to get all the patients within one group to be similar, 
each patient is different. They differ in terms of genetics, food, activities, 
previous injuries and medication. This might explain why there were 
some outliers, which were not consistent with any particular subject. 
These are non-modifiable risk factors. 
- The disease nature of flare ups could affect the results. This is difficult to 
control.  
- Sampling is another weak point. The tissues were not consistent in terms 
of content. The surgeon during the operation would take any tissue and 
hand it to the research team. The surgeon could be biased in terms of 
what tissue to provide. These sample were already available prior to the 
start of the project and could not be altered. 
- Synovitis is not necessarily the same throughout the joint. There will be 
areas of florid synovitis and others with less inflammation within the 
same joint. This will definitely affect the results.  
- Steroid injection could affect the findings but all the patients had steroid 
injections prior to their surgery and this factor was matched. 
- Smoking could not be avoided and its effect could not be ruled out in the 
young lean subjects. It was difficult to exclude the smokers as the sample 
size was too small. 
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- Although blinding was done for the ImageJ analysis, it was not possible to 
do it for the other measurements as the investigator had to examine the 
whole section for every single patient to get the best representative 
sections. Furthermore, there was a very small number of patients and the 
slides were very easy to remember from the beginning, which precluded 
the blinding.  
- Although all the data supported each other in the quantitative and semi-
quantitative assessment, bias in the examination of the samples cannot 
be excluded. 
- There was no pathologist support in this research project. The pathologist 
could have helped in tissue examination and selection of the 
representative sections for analysis. This was difficult to organise owing 
to the busy nature of the pathologist with interest in the synovium within 
the University of Liverpool.  
- This project is trying to relate a very minute tissue sample to the patient 
and it is difficult to draw major conclusions. 
- Although IHC is a well-established, largely accepted technique in both 
clinical and experimental parts of medical research, it has some 
limitations. The results vary for technical reasons, which include a lack of 
standard methodology and quality control between laboratories, 
especially with regard to antigen retrieval and type and degree of 
fixation. Moreover, it is expensive and time-consuming, and for these 
reasons it was not possible to test for more antibodies that could have 
helped in this project. 
- Finally, the sample size is too small to be able to draw a strong 
conclusion. However, sample size calculation was done prior to patient 
recruitment.  
 
5.7 Future work 
 
It is important to tackle all the challenges outlined in this project to reach more 
robust conclusions. Suggestions for future work include: 
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- Follow the same recruitment criteria to get more patients and increase the 
sample size. 
- Involvement of the pathologist from the start. 
- Have a standard approach to sample collection. I would suggest getting three 
samples from the joint, namely: medial gutter, lateral gutter and supra-
patellar pouch. The three samples should be fixed in the paraffin blocks for 
investigation separately and this could provide more detail of how the 
synovitis is expressed in the synovium. In addition, provide detailed intra-
operative findings with a photograph of the joint. This will give a better 
perspective of what is actually happening. This way we can relate the small 
tissue sample to the patient. 
- Blinding of the investigator to the samples is very important and will add a lot 
of strength to the study.  
- Vascular anatomy and assessment of smooth muscle cells. This could be done 
using markers of synthesis and contractile phenotype of smooth muscle cells. 
- It would be interesting to see the type of macrophage in the synovium and 
relate it to the circulating macrophages in the plasma. 
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6. CONCLUSION 
 
OA is a complex, multifactorial pathology. It is the nature of the disease that 
makes it very difficult to identify the cause of early OA in obese people. Every patient 
is different from the others, even within the same group. These factors have been 
discussed in the challenges section (section 5.6). Despite the difficulties that have 
been encountered in this research project and the small number of samples, several 
conclusions can be made from this research, which can be summarised as follows: 
 
1- OA is a complex multifactorial pathology with multiple confounding factors 
that could affect the results of any study. 
2- Vascular density was not significantly different among all patients. 
3- Vascular wall thickness and distance from the joint were greater in the young 
age groups and highest in the young obese group. 
4- Vascular hyperplasia may suggest atherosclerosis, which is an indication of a 
systemic manifestation of adiposity. 
5- The vascular dysfunction leads to failure of tissue nutrition, which contributes 
to the inflammatory response owing to the constant hypoxic drive, which 
causes the inflammation and early development of OA.  
6- The old age group exhibited a lower inflammatory response compared to the 
younger group. 
7- Obese patients showed the highest inflammatory response among all the 
groups. 
8- Increased fat cell diameter was associated with more inflammatory cells and 
was associated with vascular changes (increase in vascular wall thickness and 
density in the fatty sections).  
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7.    APPENDICES: 
7.1    Appendix: 1 
 
 
APPENDIX 1: Study Flowchart:  
 
Orthopaedic outpatient clinics (NHS)  
Assessed for eligibility 
Inclusion criteria: 
 Patient is willing and able to give informed consent for participation in 
the study 
 Age < 60 with BMI >30 
 Age <60  with BMI <30 
 Aged >70 with BMI < 30  
 Diagnosed with idiopathic  OA 
 Undergoing primary arthroplasty 
 
Excluded: 
those screened 
who do not meet 
the inclusion 
criteria or do 
meet the 
exclusion criteria 
Informed Consent 
Baseline data 
collection 
Demographics 
BMI 
 
Surgery: Primary Arthroplasty  
>70 (BMI <30) <60 (BMI >30) 
Histology and IHC study 
Collect data and analyse 
<60 (BMI <30) 
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7.2    Appendix: 2  
Heat-induced Epitope Retrieval Using the Dako PT-Link & 
Immunohistochemistry – use of the DAKO autostainer 
 
 
Introduction: 
 
The DAKO Autostainer is an automated slide processing system designed to 
automate manual staining methods routinely used in immunocytochemistry. 
 
Each staining run can process 1 to 48 slides.  Slides are secured in a horizontal 
position and reagents are dispensed onto the tissue by use of Teflon-coated 
pipettes.  Incubations proceed at room temperature and individual slides can be 
programmed to receive different reagents.  The system provides intuitive 
programming routines, reagent and slide loading maps and Start/Finish run time 
displays. 
 
Heat-induced Epitope Retrieval Using the Dako PT-Link  
 
 
1. The PT-Link was turned on to begin heating to 65°C to begin 
(approx 20 minutes).  
2. Slides were labelled with antibody, dilution and date, using a 
pencil. 
3. Once 65°C is reached, the slides were placed in a staining rack 
(frosted end towards the top), which was placed in the PT-
Link (in high PH medium). 
4. The lid was closed and the heated started (The PT Link will 
heat to 96°C, hold for 20 minutes, and return to 65°C (approx 
1 hour 10 minutes) 
5. After PT-Link, the slides were washed with Envision Flex-
Wash buffer for 5-15 minutes.  
6. The slides were not allowed to get dry throughout the 
staining procedure.  
 
1. Marking up & preparation of slides for the DAKO Autostainer 
 
 Slides prepared  
 PT Link retrievals was done  
 
2. Preparing and programming the DAKO Autostainer  
 
 Hazardous waste container was checked to ensure enough capacity 
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to accommodate waste from staining run. 
 Ensured the levels of 1x FLEX wash buffer and de-ionized water in 
containers were sufficient for run requirements. 
 All reagents required for staining run were brought to room 
temperature.   
 The computer was programmed according to the standard steps of 
IHC staining.  
 Once all the antibodies and all other reagents have been prepared, 
they were loaded in the machine. 
 Following antigen retrieval, the slides were soaked in a rinse station 
containing EnvisionTM FLEX Wash Buffer for 5 mins prior to loading 
onto the Autostainer. 
 The slides were correctly loaded into the slide racks according to the 
programmed map.  
 The autostainer lid was closed and the Start Run sequence was 
initiated. 
 The run included: 
 Envision-Flex block incubatation at room temperature for 5 
minutes. 
 Incubate primary antibody after dilution with appropriate 
concentration using antibody diluent (Envision-Flex) for 30 
minutes. 
 Appropriate linker (i.e. mouse for mouse primary antibody) 
was added and incubated at room temperature for 15 
minutes. 
 HRP was added and incubated at room temperature for 20 
minutes. 
 DAB was finally added and incubated at room temperature 
for 20 minutes.  
 Transfer slides to horse-shaped rack.  
 The slides were unloaded and placed into rack in bath of 
dH2O 
 The autostainer was turned off after the complete run. 
 
3. Counterstaining and mounting the slides 
 Counterstain with Haematoxylin solution for 1 min was done 
 Then the slides were Dipped in acid alcohol and rinsed in tap water 
 Then Dipped in ammonia water for 30 sec and rinsed in tap water before 
returning slides to bath of dH2O. 
 The slides were dehydrated through five changes of IMS (Industrial 
Methylated Spirits) and 2x xylene in the fume hood. 
 Finally, the slides were mounted in DPX.  
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7.3    Appendix: 3 
 
KNEE  
 
SF-12	(Short-Form)	
Question	1	
	
In	general,	would	you	say	your	health	is	excellent,	very	good,	good,	fair,	or	poor?	
 
								Excellent																																Very	Good																														Good																																				Fair																																					Poor	
 
 
The	following	items	are	about	activities	you	might	do	during	a	typical	day.	
	
	Question	2	
	
Does	your	health	now	limit	you	 in	 these	activities?	 If	so,	how	much?	First,	moderate	activities	such	as	
moving	a	table,	pushing	a	vacuum	cleaner,	bowling	or	playing	golf.	Does	your	health	now	limit	you	a	lot,	
limit	you	a	little,	or	not	limit	you	at	all.	
  
					Limited	a	lot																																																											Limited	a	little																																																									Not	limited	at	all	
 
Question	3		
	
Climbing	several	flights	of	stairs.	Does	your	health	now	limit	you	a	lot,	limit	you	a	little,	or	not	limit	you	
at	all?	
 
 
					Limited	a	lot																																																											Limited	a	little																																																									Not	limited	at	all	
 
						
Question	4	
	
During	the	past	four	weeks,	have	you	accomplished	less	than	you	would	like	as	a	result	of	your	physical	
health?	
 
									No																																																																Yes		
 
Question	5	
	
During	the	past	four	weeks,	were	you	limited	in	the	kind	of	work	or	other	regular	activities	you	do	as	a	
result	of	your	physical	health?	
 
					No																																																																Yes		
 
	
Question	6	
	
During	 the	 past	 four	 weeks,	 have	 you	 accomplished	 less	 than	 you	 would	 like	 to	 as	 a	 result	 of	 any	
emotional	problems,	such	as	feeling	depressed	or	anxious?	
 
						No																																																																Yes		
 
	
	
Question	7	
	
During	 the	past	 four	weeks,	did	you	not	do	work	or	other	 regular	activities	 as	 carefully	 as	usual	 as	 a	
result	of	any	emotional	problems	such	as	feeling	depressed	or	anxious?	
 
							No																																																																		Yes		
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Question	8	
	
During	the	past	four	weeks,	how	much	did	pain	interfere	with	your	normal	work,	including	both	work	
outside	 the	 home	 and	 housework?	 Did	 it	 interfere	 not	 at	 all,	 slightly,	 moderately,	 quite	 a	 bit,	 or		
extremely?	
	
Not	at	all																								Slightly																										Moderately																															Quite	a	bit																								Extremely	
	
	
These	questions	are	about	how	you	feel	and	how	things	have	been	with	you	during	the	past	4	weeks.	For	
each	question,	please	give	the	one	answer	that	comes	closest	to	the	way	you	have	been	feeling.	
	
Question	9	
	
How	much	 time	during	 the	past	4	weeks	have	you	 felt	 calm	and	peaceful?	All	of	 the	 time,	most	of	 the	
time,	a	good	bit	of	the	time,	some	of	the	time,	a	little	of	the	time,	or	none	of	the	time?	
	
						All	of	the	time																																																							Most	of	the	time																																																		A	good	bit	of	the	time	
	
						Some	of	the	time																																																		A	little	of	the	time																																															None	of	the	time	
		
Question	10	
	
How	much	of	the	time	during	the	past	4	weeks	did	you	have	a	lot	of	energy?	All	of	the	time,	most	of	the	
time,	a	good	bit	of	the	time,	some	of	the	time,	a	little	of	the	time,	or	none	of	the	time?	
	
						All	of	the	time																																																							Most	of	the	time																																																		A	good	bit	of	the	time	
	
						Some	of	the	time																																																		A	little	of	the	time																																															None	of	the	time	
	
Question	11	
	
How	much	time	during	the	past	4	weeks	have	you	felt	down?	All	of	the	time,	most	of	the	time,	a	good	bit	
of	the	time,	some	of	the	time,	a	little	of	the	time,	or	none	of	the	time?	
	
						All	of	the	time																																																							Most	of	the	time																																																		A	good	bit	of	the	time	
	
						Some	of	the	time																																																		A	little	of	the	time																																														None	of	the	time	
	
	
Question	12	
	
During	 the	 past	 4	 weeks,	 how	 much	 of	 the	 time	 has	 your	 physical	 health	 or	 emotional	 problems	
interfered	with	your	social	activities	like	visiting	with	friends,	relatives	etc?	All	of	the	time,	most	of	the	
time,	some	of	the	time,	a	little	of	the	time,	or	none	of	the	time?	
	
					All	of	the	time																																																						Most	of	the	time																																																	Some	of	the	time			
	
					A	little	of	the	time																																														None	of	the	time	
		
							
		
Total	Score:	
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WOMAC	Knee	Score	
	
INSTRUCTIONS:	This	survey	asks	for	your	view	about	your	knee.	This	information	will	help	us	keep	track	of	how	you	feel	
about	your	knee	and	how	well	you	are	able	to	do	your	usual	activities.		
Answer	every	question	by	ticking	the	appropriate	box.	If	you	are	unsure	about	how	to	answer	a	question,	please	
give	the	best	answer	you	can.	
	
Symptoms	-	These	questions	should	be	answered	thinking	of	your	knee	symptoms	during	the	last	week.		
S1.	Do	you	have	swelling	in	your	knee?	
		
Never	 Often	 Rarely	 Sometimes	 Always	
	
			
S2.	Do	you	feel	grinding,	hear	clicking	or	any	other	type	of	noise	when	your	knee	moves?		
		
Never	 Often	 Rarely	 Sometimes	 Always	
	
		
	S3.	Does	your	knee	catch	or	hang	up	when	moving?		
		
Never	 Often	 Rarely	 Sometimes	 Always	
	
		
	S4.	Can	you	straighten	your	knee	fully?		
		
		Never	 Often	 Rarely	 Sometimes	 Always	
	
S5.	Can	you	bend	your	knee	fully?		
		
		Never	 Often	 Rarely	 Sometimes	 Always	
	
	Stiffness	-	The	following	questions	concern	the	amount	of	joint	stiffness	you	have	experienced	during	
the	last	week	in	your	knee.	Stiffness	is	a	sensation	of	restriction	or	slowness	in	the	ease	with	which	you	
move	your	knee	joint.		
		
S6.	How	severe	is	your	knee	joint	stiffness	after	first	wakening	in	the	morning?		
		
None	 Mild	 Moderate	 Severe	 Extreme	
	
		
S7.	How	severe	is	your	knee	stiffness	after	sitting,	lying	or	resting	later	in	the	day?		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
Pain1	
		
P1.	How	often	do	you	experience	knee	pain?		
		
Never	 Monthly	 Weekly	 Daily	 Always	
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		What	amount	of	knee	pain	have	you	experienced	the	last	week	during	the	following	activities?		
		
P2.	Twisting/pivoting	on	your	knee	
	
None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		P3.	Straightening	knee	fully	
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
P4.	Bending	knee	fully		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
P5.	Walking	on	flat	surface		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
P6.	Going	up	or	down	stairs		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
P7.	At	night	while	in	bed		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
	
P8.	Sitting	or	lying		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
P9.	Standing	upright		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
Function,	daily	 living	 -	The	 following	questions	concern	your	physical	 function.	By	 this	we	mean	your	
ability	to	move	around	and	to	look	after	yourself.	For	each	of	the	following	activities	please	indicate	the	
degree	of	difficulty	you	have	experienced	in	the	last	week	due	to	your	knee.		
		
Al.	Descending	stairs		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A2.	Ascending	stairs		
		
None	 Mild	 Moderate	 Severe	 Extreme	
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For	each	of	the	following	activities	please	indicate	the	degree	of	difficulty	you	have	experienced	in	the	
last	week	due	to	your	knee.		
		
A3.	Rising	from	sitting		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A4.	Standing		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
A5.	Bending	to	floor/pick	up	an	object		
				
None	 Mild	 Moderate	 Severe	 Extreme	
	
				
A6.	Walking	on	flat	surface		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A7.	Getting	in/out	of	car		
	
	None	 Mild	 Moderate	 Severe	 Extreme	
		
			
A8.	Going	shopping		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
	
		A9.	Putting	on	socks/stockings		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
		A10.	Rising	from	bed		
				
None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A11.	Taking	off	socks/stockings		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A12.	Lying	in	bed	(turning	over,	maintaining	knee	position)		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
A13.	Getting	in/out	of	bath		
		
		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
	A14.	Sitting		
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		None	 Mild	 Moderate	 Severe	 Extreme	
	
		
		A15.	Getting	on/off	toilet		
		
None	 Mild	 Moderate	 Severe	 Extreme	
		
			
For	each	of	the	following	activities	please	indicate	the	degree	of	difficulty	you	have	experienced	in	the	
last	week	due	to	your	knee			
	
A16.	Heavy	domestic	duties	(moving	heavy	boxes,	scrubbing	floors,	etc)		
		
		Never	 Rarely	 Sometimes	 Often	 Always	
	
		
		A17.	Light	domestic	duties	(cooking,	dusting,	etc)		
		
Never	 Rarely	 Sometimes	 Often	 Always	
		
Thank	you	very	much	for	completing	all	the	questions	in	this	questionnaire.																																																																																																																																																								
	
	
	
Notes:	
	
	
	
	
	
	
Total	Score:	
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